

Efficacy and safety of belimumab in patients with active
randomised, placebo-controlled, phase 3 trial

Lancet, The

377, 721-731

DOI: [10.1016/s0140-6736\(10\)61354-2](https://doi.org/10.1016/s0140-6736(10)61354-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Training and evaluation in SMEs: Manufacturing enterprises in the West Midlands. <i>Local Economy</i> , 1993, 8, 143-154.	1.4	14
2	Pathology of Hematopoietic Stem Cell Transplantation. , 0, , 260-293.		0
3	Measuring outcomes in systemic lupus erythematosus clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 455-468.	1.4	40
5	Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2011, 365, 2110-2121.	27.0	2,265
6	Belimumab. <i>Drugs</i> , 2011, 71, 2435-2444.	10.9	26
7	Toward Better Treatment for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2011, 365, 1929-1930.	27.0	7
8	BAFF and selection of autoreactive B cells. <i>Trends in Immunology</i> , 2011, 32, 388-394.	6.8	141
9	Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 423-438.	0.3	57
10	Belimumab for systemic lupus erythematosus. <i>Lancet, The</i> , 2011, 377, 2079-2080.	13.7	6
11	BLISS! Lupus learns its lessons. <i>Lancet, The</i> , 2011, 377, 693-694.	13.7	8
12	Belimumab for systemic lupus erythematosus. <i>Lancet, The</i> , 2011, 377, 2080.	13.7	8
13	Primary Sjögren's Syndrome: Current Pathophysiological, Diagnostic and Therapeutic Advances. , 0, , .		0
14	BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis. <i>PLoS ONE</i> , 2011, 6, e23629.	2.5	60
15	Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 373-379.	2.7	49
16	Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 390-397.	1.6	14
17	Belimumab: the first US FDA approved biological therapy for systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 373-377.	0.3	4
18	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Yearbook of Medicine</i> , 2011, 2011, 18-19.	0.1	0
19	Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , 2011, 1, 1555-1561.	0.0	0

#	ARTICLE	IF	CITATIONS
20	Signaling by the tumor necrosis factor receptor superfamily in B cell biology and disease. <i>Immunological Reviews</i> , 2011, 244, 115-133.	6.0	257
21	Landmark lupus approval opens door for next wave of drugs. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 243-245.	46.4	5
22	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2011, 39, 486-491.	0.4	2
23	B-cells and their targeting in rheumatoid arthritis – Current concepts and future perspectives. <i>Autoimmunity Reviews</i> , 2011, 11, 28-34.	5.8	85
24	Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. <i>Autoimmunity Reviews</i> , 2011, 11, 56-60.	5.8	51
26	Integrating Autoimmune Risk Loci with Gene-Expression Data Identifies Specific Pathogenic Immune Cell Subsets. <i>American Journal of Human Genetics</i> , 2011, 89, 496-506.	6.2	159
27	Basophils and Autoreactive IgE in the Pathogenesis of Systemic Lupus Erythematosus. <i>Current Allergy and Asthma Reports</i> , 2011, 11, 378-387.	5.3	39
28	Current drugs in systemic lupus erythematosus. <i>Drug Development Research</i> , 2011, 72, 561-572.	2.9	1
29	Belimumab therapy for systemic lupus erythematosus and potential treatment of rheumatoid arthritis. <i>Drug Development Research</i> , 2011, 72, 623-633.	2.9	1
30	B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. <i>Arthritis and Rheumatism</i> , 2011, 63, 3931-3941.	6.7	59
31	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
32	Research Highlights. <i>Immunotherapy</i> , 2011, 3, 1293-1295.	2.0	2
33	Improving the assessment of children with JIA. <i>Nature Reviews Rheumatology</i> , 2011, 7, 442-444.	8.0	6
34	Systemic lupus erythematosus - an update. <i>Drug and Therapeutics Bulletin</i> , 2011, 49, 81-84.	0.3	5
35	Targeting B cells in SLE: good news at last!. <i>Nature Reviews Rheumatology</i> , 2011, 7, 255-256.	8.0	10
36	Basophils, IgE, and Autoantibody-Mediated Kidney Disease. <i>Journal of Immunology</i> , 2011, 186, 6083-6090.	0.8	19
37	Targeting the BlyS family in autoimmunity: a tale of mouse and man. <i>Clinical Investigation</i> , 2011, 1, 951-967.	0.0	5
38	Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis. <i>Immunotherapy</i> , 2011, 3, 1431-1440.	2.0	1

#	ARTICLE	IF	CITATIONS
39	Antibody-Mediated Coengagement of Fc γ RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 186, 4223-4233.	0.8	142
40	IFN- γ Confers Resistance of Systemic Lupus Erythematosus Nephritis to Therapy in NZB/W F1 Mice. <i>Journal of Immunology</i> , 2011, 187, 1506-1513.	0.8	44
41	Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials. <i>Journal of Rheumatology</i> , 2011, 38, 2395-2399.	2.0	45
42	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 437-451.	3.1	3
43	Lupus nephritisâ€”winning a few battles but not the war. <i>Nature Reviews Rheumatology</i> , 2011, 7, 441-442.	8.0	15
44	BAFF/APRIL Inhibition Decreases Selection of Naive but Not Antigen-Induced Autoreactive B Cells in Murine Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 187, 6571-6580.	0.8	27
45	Belimumab. <i>Hospital Pharmacy</i> , 2011, 46, 519-530.	1.0	0
46	Are autoantibodies the targets of B-cell-directed therapy?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 551-556.	8.0	22
47	Belimumab: First targeted biological treatment for systemic lupus erythematosus. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2011, 2, 317-319.	0.4	53
48	Belimumab in systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 11-23.	2.5	10
49	Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. <i>Autoimmune Diseases</i> , 2012, 2012, 1-6.	0.6	18
50	A Rare Case of Prototheca Algaemia in a Patient with Systemic Lupus Erythematosus and Recent Belimumab Infusion. <i>Case Reports in Immunology</i> , 2012, 2012, 1-4.	0.4	3
51	Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. <i>Current Opinion in Rheumatology</i> , 2012, 24, 451-456.	4.3	40
53	Conference Scene: Shining lights on the future of autoimmunity in Asia. <i>Immunotherapy</i> , 2012, 4, 263-267.	2.0	0
54	Targeting BLYS in Systemic Lupus Erythematosus. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2012, 6, 91-96.	3.6	2
55	Trial of SLE therapies in real-world settings. <i>Nature Reviews Rheumatology</i> , 2012, 8, 128-130.	8.0	2
56	Review of biologics in children with rheumatic diseases. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 81-93.	0.3	0
57	Approval on a knife edge. <i>Nature Biotechnology</i> , 2012, 30, 26-29.	17.5	5

#	ARTICLE	IF	CITATIONS
59	Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. <i>Rheumatology</i> , 2012, 51, 1814-1819.	1.9	44
60	B Cell-Derived IL-10 Does Not Regulate Spontaneous Systemic Autoimmunity in MRL. <i> Faslpr</i> Mice. <i>Journal of Immunology</i> , 2012, 188, 678-685.	0.8	94
61	New and future therapies for lupus nephritis. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 134-140.	1.3	12
62	Animal Models of Molecular Pathology. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 105, 321-370.	1.7	40
63	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. <i>Biologics: Targets and Therapy</i> , 2012, 6, 347.	3.2	7
64	Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	16
65	Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-11.	1.6	44
66	Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1343-1349.	0.9	343
67	Does Belimumab Reduce Disease Activity in Adults with Systemic Lupus Erythematosus?. <i>Clinical Medicine Reviews in Therapeutics</i> , 2012, 4, 71-78.	0.2	0
68	Lupus nephritis. How latest insights into its pathogenesis promote novel therapies. <i>Current Opinion in Rheumatology</i> , 2012, 24, 457-465.	4.3	21
70	Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity. <i>Current Medicinal Chemistry</i> , 2012, 19, 438-453.	2.4	10
71	Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity. <i>Current Pharmaceutical Design</i> , 2012, 18, 4526-4536.	1.9	3
73	11. Recent Progress in the Treatment of Lupus Nephritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2012, 101, 134b-134b.	0.0	0
75	Prognostic Impact of Atypical Presentation in Pediatric Systemic Lupus Erythematosus: Results from a Multicenter Study. <i>Yearbook of Pediatrics</i> , 2012, 2012, 340-343.	0.2	0
76	Potential Immunologic Targets for Treating Fibrosis in Systemic Sclerosis: A Review Focused on Leukocytes and Cytokines. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 281-296.	3.4	22
77	The pathogenesis of systemic lupus erythematosus—an update. <i>Current Opinion in Immunology</i> , 2012, 24, 651-657.	5.5	258
79	Taming lupus—a new understanding of pathogenesis is leading to clinical advances. <i>Nature Medicine</i> , 2012, 18, 871-882.	30.7	390
80	Systemic Lupus Erythematosus in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2012, 59, 345-364.	1.8	214

#	ARTICLE	IF	CITATIONS
81	The Treatment of Lupus: General Principles. , 2012, , 53-66.		0
82	Detection of biomarkers using recombinant antibodies coupled to nanostructured platforms. Nano Reviews, 2012, 3, 17240.	3.7	50
83	Interleukin-17 Cytokines Are Critical in Development of Fatal Lupus Glomerulonephritis. Immunity, 2012, 37, 1104-1115.	14.3	151
84	Immunotherapies in Rheumatologic Disorders. Medical Clinics of North America, 2012, 96, 475-496.	2.5	30
85	CD22 and Autoimmune Disease. International Reviews of Immunology, 2012, 31, 363-378.	3.3	43
86	Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Annals of the Rheumatic Diseases, 2012, 71, 75-79.	0.9	150
87	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care and Research, 2012, 64, 797-808.	3.4	1,119
89	Lupus nephritis: A critical review. Autoimmunity Reviews, 2012, 12, 174-194.	5.8	199
90	B-cell targeted treatments for lupus: The journey counts as much as the destination. Joint Bone Spine, 2012, 79, 437-440.	1.6	1
91	Comparative Safety of Therapies in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2012, 38, 795-807.	1.9	1
92	Semaphorin 3A â€“ a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus, 2012, 21, 1266-1270.	1.6	25
93	Belimumab for the management of systemic lupus erythematosus. Expert Opinion on Biological Therapy, 2012, 12, 957-963.	3.1	6
94	SÃ¡ndrome de SjÃ¡rgren primario. EMC - Aparato Locomotor, 2012, 45, 1-15.	0.1	0
96	Immunotherapy in Renal Diseases. Medical Clinics of North America, 2012, 96, 545-564.	2.5	4
97	Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Research and Therapy, 2012, 14, 202.	3.5	28
98	Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Research and Therapy, 2012, 14, S1.	3.5	78
99	Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Research and Therapy, 2012, 14, S3.	3.5	20
100	Unmet medical needs in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, S4.	3.5	127

#	ARTICLE	IF	CITATIONS
101	Abatacept in the treatment of lupus. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1399-1406.	3.1	15
103	Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2012, 26, 195-199.	4.6	6
104	Optimization of current and future therapy for autoimmune diseases. <i>Nature Medicine</i> , 2012, 18, 59-65.	30.7	79
105	Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1833-1838.	0.9	350
106	Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial. <i>Journal of Rheumatology</i> , 2012, 39, 1632-1640.	2.0	80
107	Delayed diagnosis of systemic lupus erythematosus due to misinterpretation of dengue serology: comments on the article by Santosa et al. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 410-411.	1.1	2
108	The state of therapy for removal of alloantibody producing plasma cells in transplantation. <i>Seminars in Immunology</i> , 2012, 24, 143-147.	5.6	19
109	The discovery and development of belimumab: the anti-BLySâ€“lupus connection. <i>Nature Biotechnology</i> , 2012, 30, 69-77.	17.5	137
110	Deciphering the role of NETs and networks in SLE. <i>Nature Reviews Rheumatology</i> , 2012, 8, 68-70.	8.0	25
111	B-cell-depleting Therapy in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2012, 125, 327-336.	1.5	66
112	Recent Progress in the Treatment of Proliferative Lupus Nephritis. <i>American Journal of Medicine</i> , 2012, 125, 642-648.	1.5	6
113	Attenuation of phosphoinositide 3-kinase Î³ signaling restrains autoimmune disease. <i>Journal of Autoimmunity</i> , 2012, 38, 381-391.	6.5	45
114	Lupus: Novel therapies in clinical development. <i>European Journal of Internal Medicine</i> , 2012, 23, 212-218.	2.2	21
115	Longâ€“term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
116	To Market, To Marketâ€“2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.9	23
117	Future Trends in Organ Transplant Recipients â€“ Important Issues for Dermatologists. <i>Current Problems in Dermatology</i> , 2012, 43, 71-80.	0.7	3
118	The role of B cellâ€“activating factor in autoimmune myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 60-67.	3.8	18
119	Systemic Lupus Erythematosus: An Overview. <i>Social Work in Health Care</i> , 2012, 51, 576-586.	1.6	45

#	ARTICLE	IF	CITATIONS
120	B-cell activating factor targeted therapy and lupus. <i>Arthritis Research and Therapy</i> , 2012, 14, S2.	3.5	27
121	Belimumab: A BlyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 143-149.	4.7	23
122	The genetics of type I interferon in systemic lupus erythematosus. <i>Current Opinion in Immunology</i> , 2012, 24, 530-537.	5.5	113
123	The Crystal Structure of the Catalytic Domain of the NF- κ B Inducing Kinase Reveals a Narrow but Flexible Active Site. <i>Structure</i> , 2012, 20, 1704-1714.	3.3	57
126	Depletion of B2 but Not B1a B Cells in BAFF Receptor-Deficient ApoE ^{-/-} / α ^{-/-} Mice Attenuates Atherosclerosis by Potently Ameliorating Arterial Inflammation. <i>PLoS ONE</i> , 2012, 7, e29371.	2.5	143
127	Fatigue in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 217-227.	0.3	72
128	Cellular Targeting in Autoimmunity. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 495-510.	5.3	11
129	The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 53-69.	1.4	10
130	Unraveling the autoimmune translational research process layer by layer. <i>Nature Medicine</i> , 2012, 18, 35-41.	30.7	50
131	Late-Onset Systemic Lupus Erythematosus. <i>Drugs and Aging</i> , 2012, 29, 181-189.	2.7	78
132	Rheumatologie aus der Praxis. , 2012, , .		1
133	Current state of evidence on "off-label"™ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland " a consensus report. <i>Lupus</i> , 2012, 21, 386-401.	1.6	71
134	APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R252.	3.5	57
135	B Cell Targeted Therapy in Rheumatic Disease. <i>Journal of Rheumatic Diseases</i> , 2012, 19, 67.	1.1	0
136	New treatment options for lupus – a focus on belimumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 33.	2.0	17
137	Update on the Management of Systemic Lupus Erythematosus from a Pediatric Nephrology Perspective. <i>Current Rheumatology Reviews</i> , 2012, 8, 30-38.	0.8	0
138	Cytokines and Systemic Lupus Erythematosus. , 0, , .		0
139	The Interplay of IL-21 and BAFF in the Formation and Maintenance of Human B Cell Memory. <i>Frontiers in Immunology</i> , 2012, 3, 2.	4.8	31

#	ARTICLE	IF	CITATIONS
140	Novel Pharmacologic Therapies in the Treatment of Systemic Lupus Erythematosus. Hanyang Medical Reviews, 2012, 32, 83.	0.4	0
141	Treatment of systemic lupus erythematosus. Part II. The role of biologic agents. Reumatologia, 2012, 6, 515-521.	1.1	0
143	The Outlook of Belimumab in the Treatment of Systemic Lupus Erythematosus. Journal of Developing Drugs, 2012, 01, .	0.9	0
144	Recommendations for diagnosis and treatment Treatment of systemic lupus erythematosus. Part I. Guidelines for the treatment of systemic lupus erythematosus. Reumatologia, 2012, 5, 383-389.	1.1	1
145	B-cell depletion in the treatment of lupus nephritis. Nature Reviews Nephrology, 2012, 8, 505-514.	9.6	78
146	BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. IUBMB Life, 2012, 64, 595-602.	3.4	35
147	BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunology and Cell Biology, 2012, 90, 293-303.	2.3	79
148	Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis and Rheumatism, 2012, 64, 1610-1619.	6.7	41
149	The landscape after LUNAR: Rituximab's craterâ€filled path. Arthritis and Rheumatism, 2012, 64, 962-965.	6.7	34
150	Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2328-2337.	6.7	315
151	Disease activity, severity, and damage in the UK juvenileâ€onset systemic lupus erythematosus cohort. Arthritis and Rheumatism, 2012, 64, 2356-2365.	6.7	170
152	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
155	Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?. Current Rheumatology Reports, 2012, 14, 303-309.	4.7	32
156	Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?. Current Rheumatology Reports, 2012, 14, 318-323.	4.7	17
157	The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. Current Rheumatology Reports, 2012, 14, 295-302.	4.7	31
158	Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?. Current Rheumatology Reports, 2012, 14, 324-333.	4.7	14
159	Belimumab and the Clinical Data. Current Rheumatology Reports, 2012, 14, 310-317.	4.7	11
161	New developments in the treatment of systemic lupus erythematosus. Pediatric Nephrology, 2012, 27, 727-732.	1.7	15

#	ARTICLE	IF	CITATIONS
162	Treatment of systemic lupus erythematosus: new advances in targeted therapy. <i>Annals of the New York Academy of Sciences</i> , 2012, 1247, 138-152.	3.8	38
163	Emerging therapies for systemic lupus erythematosus – Focus on targeting interferon-alpha. <i>Clinical Immunology</i> , 2012, 143, 210-221.	3.2	76
164	Belimumab: Review of Use in Systemic Lupus Erythematosus. <i>Clinical Therapeutics</i> , 2012, 34, 1006-1022.	2.5	33
165	How to treat refractory arthritis in lupus?. <i>Joint Bone Spine</i> , 2012, 79, 347-350.	1.6	8
166	The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment. <i>Autoimmunity Reviews</i> , 2012, 11, 326-329.	5.8	86
167	Cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2012, 25, 99-111.	1.7	10
168	Janus-like effects of type I interferon in autoimmune diseases. <i>Immunological Reviews</i> , 2012, 248, 23-35.	6.0	45
170	Biologics in oral medicine: Sjogren syndrome. <i>Oral Diseases</i> , 2013, 19, 121-127.	3.0	10
171	To target or not to target APRIL in systemic lupus erythematosus: that is the question!. <i>Arthritis Research and Therapy</i> , 2013, 15, 107.	3.5	6
172	Aberrant B Cell Selection and Activation in Systemic Lupus Erythematosus. <i>International Reviews of Immunology</i> , 2013, 32, 445-470.	3.3	28
173	Novel therapeutic agents in clinical development for systemic lupus erythematosus. <i>BMC Medicine</i> , 2013, 11, 120.	5.5	15
174	Renal involvement in autoimmune connective tissue diseases. <i>BMC Medicine</i> , 2013, 11, 95.	5.5	100
175	Biologic therapy for autoimmune diseases: an update. <i>BMC Medicine</i> , 2013, 11, 88.	5.5	202
176	Top 10 Developments in Lupus Nephritis. <i>Current Rheumatology Reports</i> , 2013, 15, 358.	4.7	4
177	Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. <i>Immunologic Research</i> , 2013, 56, 376-381.	2.9	12
178	The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2013, 7, 309-312.	4.2	4
179	Indications for use and safety of rituximab in childhood renal diseases. <i>Pediatric Nephrology</i> , 2013, 28, 1001-1009.	1.7	11
180	B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 761-772.	3.0	10

#	ARTICLE	IF	CITATIONS
181	Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. <i>Arthritis and Rheumatism</i> , 2013, 65, 2143-2153.	6.7	152
184	Lupus Nephritis: Novel Treatments and Diagnostic Approaches. <i>Current Pediatrics Reports</i> , 2013, 1, 41-51.	4.0	0
185	Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-blind, Phase III Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2368-2379.	6.7	272
186	The role of cytokines in the pathogenesis of systemic lupus erythematosus "from bench to bedside. <i>Nephrology</i> , 2013, 18, 243-255.	1.6	92
187	Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. <i>Lancet, The</i> , 2013, 382, 809-818.	13.7	103
188	Consenso de la Sociedad Espa±ola de ReumatologÃa sobre el uso de terapias biolÃgicas en el lupus eritematoso sistÃmico. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 281-296.	0.5	31
189	Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. <i>Lupus</i> , 2013, 22, 1286-1294.	1.6	274
190	Predictors of self-reported health-related quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2013, 52, 1651-1657.	1.9	53
191	Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. <i>Lupus</i> , 2013, 22, 63-72.	1.6	246
193	Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options. <i>The Consultant Pharmacist</i> , 2013, 28, 110-121.	0.4	92
194	Systemic Lupus Erythematosus. <i>Dental Clinics of North America</i> , 2013, 57, 631-655.	1.8	144
195	Latest advances in connective tissue disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 234-249.	2.7	10
196	Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. <i>Lupus</i> , 2013, 22, 1489-1503.	1.6	91
197	Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 309-318.	3.3	30
198	Biologics in SLE: Towards new approaches. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 341-349.	3.3	23
199	Adherence to treatment in systemic lupus erythematosus patients. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 329-340.	3.3	140
200	Targeted therapies in systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 978-986.	1.6	12
202	Minimising steroids in lupus nephritis "will B cell depletion pave the way?. <i>Lupus</i> , 2013, 22, 390-399.	1.6	25

#	ARTICLE	IF	CITATIONS
203	B-lymphocyte lineage cells and the respiratory system. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 933-957.	2.9	136
204	Phase I, Randomized, Double-blind, Placebo-controlled, Multiple Intravenous, Dose-ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 2661-2671.	6.7	86
205	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 281-296.	0.3	10
206	Enhanced Rho-associated Protein Kinase Activation in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 1592-1602.	6.7	66
207	Reprint of: B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 148, 344-358.	3.2	2
208	Recent progress in conventional and biologic therapy for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii66-ii68.	0.9	8
209	Is there an effective treatment for late-onset systemic lupus erythematosus?. <i>Aging Health</i> , 2013, 9, 437-450.	0.3	0
210	Future prospects in biologic therapy for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2013, 9, 705-720.	8.0	48
211	The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 203-215.	7.2	319
212	Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. <i>Journal of Drug Assessment</i> , 2013, 2, 40-48.	2.2	6
213	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 723-737.	3.1	23
214	The development of genome-wide association studies and their application to complex diseases, including lupus. <i>Lupus</i> , 2013, 22, 1205-1213.	1.6	13
215	B-cell targeted therapeutics in clinical development. <i>Arthritis Research and Therapy</i> , 2013, 15, S4.	3.5	92
216	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013, 15, S2.	3.5	109
217	Measuring disease activity and severity in clinical trials and the clinic: same or different?. <i>Arthritis Research and Therapy</i> , 2013, 15, .	3.5	2
218	Clinical impact of biologic therapy in the treatment of SLE. <i>Arthritis Research and Therapy</i> , 2013, 15, .	3.5	0
219	Elevated Serum BAFF Levels Are Associated With Rising Anti-double-stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 2672-2679.	6.7	128
220	Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 144-154.	1.6	106

#	ARTICLE	IF	CITATIONS
221	Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. <i>Autoimmunity Reviews</i> , 2013, 12, 752-757.	5.8	66
222	Personalizing medicine for autoimmune and inflammatory diseases. <i>Nature Immunology</i> , 2013, 14, 106-109.	14.5	35
223	The treatment of systemic lupus proliferative nephritis. <i>Pediatric Nephrology</i> , 2013, 28, 2069-2078.	1.7	7
224	Emerging and critical issues in the pathogenesis of lupus. <i>Autoimmunity Reviews</i> , 2013, 12, 523-536.	5.8	114
225	Autoantibodies. , 2013, , 273-285.		0
226	Immune Thrombocytopenia and B-Cell-Activating Factor/A Proliferation-Inducing Ligand. <i>Seminars in Hematology</i> , 2013, 50, S89-S99.	3.4	16
227	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013, 8, S46-S53.	0.4	7
229	Immunoabsorption for connective tissue disease. <i>Atherosclerosis Supplements</i> , 2013, 14, 185-189.	1.2	20
230	A Single-Arm, Phase II Study of the Anti-Blys Monoclonal Antibody Belimumab in Symptomatic Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 575-578.	0.4	7
231	Interleukin-6 <i>Trans</i> -Signaling Exacerbates Inflammation and Renal Pathology in Lupus-Prone Mice. <i>Arthritis and Rheumatism</i> , 2013, 65, 2691-2702.	6.7	38
232	Lupus eritematoso sistémico (II). <i>Medicine</i> , 2013, 11, 1966-1974.	0.0	0
233	Identify the key amino acid of BAFF binding with TACI. <i>Cellular Immunology</i> , 2013, 284, 84-90.	3.0	5
234	Clinical targeting of the TNF and TNFR superfamilies. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 147-168.	46.4	364
235	B-cell-targeted therapies in systemic lupus erythematosus. <i>Cellular and Molecular Immunology</i> , 2013, 10, 133-142.	10.5	65
236	Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2013, 12, 885-893.	5.8	84
237	Belimumab for Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2013, 368, 1528-1535.	27.0	132
238	Belimumab Therapy in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 225-235.	4.6	8
239	B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 146, 90-103.	3.2	37

#	ARTICLE	IF	CITATIONS
240	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. , 2013, , 299-326.		0
241	Aberrant B lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. <i>European Journal of Clinical Investigation</i> , 2013, 43, 866-880.	3.4	7
242	Targeting the complement system in systemic lupus erythematosus and other diseases. <i>Clinical Immunology</i> , 2013, 148, 313-321.	3.2	87
243	Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 1775-1785.	3.4	50
244	Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2013, 15, 337.	4.7	1
245	Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 711-720.	2.0	43
246	B-Cell Targeted Therapies in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 85-95.	4.6	37
247	Treatment of lupus nephritis. <i>Revue De Medecine Interne</i> , 2013, 34, A9-A11.	1.0	16
248	Novel Therapies for SLE. , 2013, , 640-647.		0
249	The future of B cell-targeted therapies in Sjögren's syndrome. <i>Immunotherapy</i> , 2013, 5, 639-646.	2.0	18
250	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , 2013, 13, 405-412.	3.5	24
251	Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID). <i>Lupus</i> , 2013, 22, 1142-1149.	1.6	74
252	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002852.	1.9	19
253	Traitement du lupus érythémateux systémique. , 2013, , 73-90.		2
254	The Pathogenesis of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1357-1366.	6.1	351
255	Children and adolescents with SLE: not just little adults. <i>Lupus</i> , 2013, 22, 1309-1319.	1.6	42
256	Race and the response to therapies for lupus: how strong is the evidence?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 471-481.	0.3	6
257	Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. <i>Rheumatology</i> , 2013, 52, 1279-1284.	1.9	43

#	ARTICLE	IF	CITATIONS
258	B-cell-targeted therapy in adult glomerulonephritis. Expert Opinion on Biological Therapy, 2013, 13, 1691-1706.	3.1	11
259	Targeting B-cells in lupus nephritis: should cautious optimism remain?. Nephrology Dialysis Transplantation, 2013, 28, 7-9.	0.7	7
260	Review of refractory lupus nephritis. International Journal of Clinical Rheumatology, 2013, 8, 61-72.	0.3	2
261	Protein Therapeutics Targeted at the TNF Superfamily. Advances in Pharmacology, 2013, 66, 51-80.	2.0	15
262	The TNF family member APRIL dampens collagen-induced arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1367-1374.	0.9	24
263	Évaluation thérapeutique dans le lupus érythémateux systémique. , 2013, , 209-223.		0
264	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 2013, 52, 1313-1322.	1.9	115
265	B Lymphocytes: Development, Tolerance, and Their Role in Autoimmunity”Focus on Systemic Lupus Erythematosus. Autoimmune Diseases, 2013, 2013, 1-17.	0.6	54
266	Development of Systemic Lupus Erythematosus in NZM 2328 Mice in the Absence of any Single BAFF Receptor. Arthritis and Rheumatism, 2013, 65, 1043-1054.	6.7	35
267	Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. Arthritis and Rheumatism, 2013, 65, 880-889.	6.7	64
268	Animal Models of SLE. , 2013, , 190-236.		10
269	Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. Journal of Rheumatology, 2013, 40, 34-39.	2.0	13
270	Challenges and opportunities in SLE clinical trials. Current Opinion in Rheumatology, 2013, 25, 606-615.	4.3	11
271	Atherosclerosis in Systemic Lupus Erythematosus. Journal of Cardiovascular Pharmacology, 2013, 62, 255-262.	1.9	62
272	New therapeutics in systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 297-303.	4.3	22
273	Has the Time Come for Routine Trimethoprim-Sulfamethoxazole Prophylaxis in Patients Taking Biologic Therapies?. Clinical Infectious Diseases, 2013, 56, 1621-1628.	5.8	19
274	Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology, 2013, 52, 1658-1666.	1.9	43
275	Quality Guidelines for Systemic Lupus Erythematosus: Slow But Steady Progress. Journal of Rheumatology, 2013, 40, 542-543.	2.0	1

#	ARTICLE	IF	CITATIONS
276	Sifalimumab, a Human Anti-Interferon- γ Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 1011-1021.	6.7	238
277	Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1830-1835.	0.9	143
278	Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. <i>Journal of Rheumatology</i> , 2013, 40, 579-589.	2.0	87
279	Humoral theory of transplantation: some hot topics. <i>British Medical Bulletin</i> , 2013, 105, 139-155.	6.9	9
281	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 873-884.	1.6	74
282	Focus on systemic lupus erythematosus in Indigenous Australians: towards a better understanding of autoimmune diseases. <i>Internal Medicine Journal</i> , 2013, 43, 227-234.	0.8	23
283	Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 349-357.	1.6	23
284	Belimumab: targeted therapy for lupus. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 4-13.	1.9	11
286	B cell biology: implications for treatment of systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 342-349.	1.6	53
287	Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. <i>Lupus</i> , 2013, 22, 1523-1525.	1.6	15
288	Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 1865-1874.	2.0	21
289	Refractory Proliferative Lupus Nephritis. <i>Journal of Pharmacy Technology</i> , 2013, 29, 265-282.	1.0	1
290	Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. <i>Lupus</i> , 2013, 22, 361-371.	1.6	18
291	Belimumab for systemic lupus erythematosus: a practice-based view. <i>Lupus</i> , 2013, 22, 372-380.	1.6	19
292	Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 383-397.	0.3	0
294	Allogenic Mesenchymal Stem Cell Transplantation Ameliorates Nephritis in Lupus Mice via Inhibition of B-Cell Activation. <i>Cell Transplantation</i> , 2013, 22, 2279-2290.	2.5	61
295	Rheumatology in the Singapore General Hospital - Looking Back, Looking Forward. <i>Proceedings of Singapore Healthcare</i> , 2013, 22, 1-3.	0.6	0
297	Elevated Pretransplantation Soluble BAFF Is Associated With an Increased Risk of Acute Antibody-Mediated Rejection. <i>Transplantation</i> , 2013, 96, 413-420.	1.0	65

#	ARTICLE	IF	CITATIONS
298	Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 1741-1749.	8.2	104
300	B cell activating factor (BAFF) induces the transcription of recombination-activating genes in transitional stage 1 B cells. <i>Central-European Journal of Immunology</i> , 2013, 3, 336-342.	1.2	1
301	The Structure and Derivation of Antibodies and Autoantibodies. , 2013, , 76-95.		3
302	The Musculoskeletal System and Bone Metabolism. , 2013, , 333-340.		3
303	SLE and Infections. , 2013, , 555-562.e1.		3
304	Clinical Measures, Metrics, and Indices. , 2013, , 563-581.		5
305	Critical Issues in Drug Development for SLE. , 2013, , 648-652.		1
307	Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 775.	2.0	45
308	Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. <i>PLoS ONE</i> , 2014, 9, e98315.	2.5	24
309	Naja naja atraVenom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-11.	1.2	10
310	Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. <i>Journal of Inflammation Research</i> , 2014, 7, 121.	3.5	37
311	Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2303.	4.3	8
312	Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance. <i>International Journal of Molecular Sciences</i> , 2014, 15, 16381-16417.	4.1	19
313	Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy. <i>World Journal of Transplantation</i> , 2014, 4, 1.	1.6	12
314	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , 2014, 6, 1165-1175.	2.0	8
315	Renal Involvement in Children with Systemic Lupus Erythematosus. , 2014, , 1-45.		0
316	Drugs derived from phage display. <i>MAbs</i> , 2014, 6, 73-85.	5.2	136
317	Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. <i>Autoimmunity Highlights</i> , 2014, 5, 33-45.	3.9	32

#	ARTICLE	IF	CITATIONS
318	Systemic lupus erythematosus: which drugs and when?. International Journal of Clinical Rheumatology, 2014, 9, 385-394.	0.3	4
320	Refractory subacute cutaneous lupus erythematosus responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 477.	0.6	14
321	Systemic Lupus Erythematosus, Treatment. , 2014, , 1184-1188.		0
322	Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets, 2014, 18, 473-489.	3.4	58
323	Restoring the balance: immunotherapeutic combinations for autoimmune disease. DMM Disease Models and Mechanisms, 2014, 7, 503-513.	2.4	84
324	Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. Frontiers in Pharmacology, 2014, 5, 265.	3.5	57
325	Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International, 2014, 2014, 1-9.	1.9	25
326	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Science and Medicine, 2014, 1, e000031.	2.7	63
327	An overview of current and future treatment methods for lupus nephritis. Expert Opinion on Orphan Drugs, 2014, 2, 169-179.	0.8	0
328	The potential role of blisibimod for the treatment of systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2014, 9, 121-134.	0.3	2
329	Which outcome measures in SLE clinical trials best reflect medical judgment?. Lupus Science and Medicine, 2014, 1, e000005.	2.7	56
330	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. Lupus Science and Medicine, 2014, 1, e000013.	2.7	5
331	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opinion on Biological Therapy, 2014, 14, 311-326.	3.1	13
332	<scp>BAFF</scp> regulates activation of self-reactive <scp>T</scp> cells through <scp>B</scp>-cell dependent mechanisms and mediates protection in <scp>NOD</scp> mice. European Journal of Immunology, 2014, 44, 983-993.	2.9	16
333	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases, 2014, 73, 183-190.	0.9	266
334	B-cell-derived IL-10 does not vitally contribute to the clinical course of glomerulonephritis. European Journal of Immunology, 2014, 44, 683-693.	2.9	5
335	Vasculitic Neuropathies and Neuropathies of Connective Tissue Diseases. , 2014, , 733-785.		4
336	CD20+ B Cell Depletion Alters T Cell Homing. Journal of Immunology, 2014, 192, 4242-4253.	0.8	24

#	ARTICLE	IF	CITATIONS
337	The pathogenesis, diagnosis and treatment of lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 502-509.	4.3	103
338	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , 2014, 26, 510-519.	4.3	28
339	Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , 2014, 26, 528-537.	4.3	48
340	Relevance of Different Results of Different Anti-Double-Stranded DNA Assays in Reporting Clinical Studies: Comment on the Article by Petri et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 479-480.	5.6	5
341	Reply. <i>Arthritis and Rheumatology</i> , 2014, 66, 480-480.	5.6	0
342	Emerging immunotherapies for rheumatoid arthritis. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 822-837.	3.3	17
343	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
344	Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	6
345	The BAFF/APRIL system in SLE pathogenesis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 365-373.	8.0	338
346	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77
347	Efficacy and Safety of Biologic Therapies for Systemic Lupus Erythematosus Treatment: Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2014, 28, 211-228.	4.6	27
348	Novel treatments for immune thrombocytopenia. <i>Presse Medicale</i> , 2014, 43, e87-e95.	1.9	21
349	In-/off-label use of biologic therapy in systemic lupus erythematosus. <i>BMC Medicine</i> , 2014, 12, 30.	5.5	21
350	A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 2234-2245.	5.6	86
351	B Cell Activation and B Cell Tolerance. , 2014, , 147-158.		2
352	Granulocytes. , 2014, , 201-215.		4
354	Treatment of Autoimmune Disease. , 2014, , 1209-1220.		0
355	Treatment of Autoimmune Disease. , 2014, , 1221-1245.		2

#	ARTICLE	IF	CITATIONS
356	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
357	Using genetic findings in autism for the development of new pharmaceutical compounds. <i>Psychopharmacology</i> , 2014, 231, 1063-1078.	3.1	27
359	Anti-“B Cell Antibody Therapies for Inflammatory Rheumatic Diseases. <i>Annual Review of Medicine</i> , 2014, 65, 263-278.	12.2	33
360	Pragmatic approaches to therapy for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014, 10, 97-107.	8.0	81
361	Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. <i>Nature Reviews Rheumatology</i> , 2014, 10, 23-34.	8.0	50
364	Low-dose Irinotecan Improves Advanced Lupus Nephritis in Mice Potentially by Changing DNA Relaxation and Anti-“Double-stranded DNA Binding. <i>Arthritis and Rheumatology</i> , 2014, 66, 2259-2269.	5.6	11
365	Serum Levels of B-Cell Activating Factor in Chronic Hepatitis B Virus Infection: Association with Clinical Diseases. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 787-794.	1.2	17
366	The efficacy of novel B cell biologics as the future of SLE treatment: A review. <i>Autoimmunity Reviews</i> , 2014, 13, 1094-1101.	5.8	97
367	Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 428-430.	1.1	27
368	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	2.0	149
369	Belimumab in Systemic Lupus Erythematosus – What Can Be Learned from Longterm Observational Studies?. <i>Journal of Rheumatology</i> , 2014, 41, 192-193.	2.0	3
370	Investigational drugs for treating psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1001-1016.	4.1	7
372	Biologics in systemic lupus erythematosus: current options and future perspectives. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 440-447.	0.5	7
373	Update on belimumab for the management of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1701-1708.	3.1	9
374	New insights into the pathogenesis and management of lupus in children. <i>Archives of Disease in Childhood</i> , 2014, 99, 563-567.	1.9	27
375	Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 684-692.	2.1	6
376	What Is an Autoantibody?. , 2014, , 13-20.		1
377	Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment. <i>Journal of Rheumatology</i> , 2014, 41, 688-697.	2.0	79

#	ARTICLE	IF	CITATIONS
378	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 838-844.	0.9	123
379	Interplay of Infections, Autoimmunity, and Immunosuppression in Systemic Lupus Erythematosus. <i>International Reviews of Immunology</i> , 2014, 33, 330-363.	3.3	49
380	The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 983-990.	1.9	0
381	Infections and systemic lupus erythematosus. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1467-1475.	2.9	83
382	Recent advances in the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 89-100.	0.3	0
383	Update on B-cell targeted therapies for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 773-788.	3.1	6
384	Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2014, 54, 60-71.	6.5	39
386	Cerebral large vessel vasculitis in systemic lupus erythematosus. <i>Lupus</i> , 2014, 23, 1417-1421.	1.6	22
387	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 401-406.	0.9	23
388	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 182-193.	1.4	6
389	Emerging biological therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 303-322.	2.4	21
390	Hydroxychloroquine: A multifaceted treatment in lupus. <i>Presse Medicale</i> , 2014, 43, e167-e180.	1.9	153
391	Post-marketing Experiences with Belimumab in the Treatment of SLE Patients. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 507-517.	1.9	21
392	Systemic lupus erythematosus. <i>Lancet, The</i> , 2014, 384, 1878-1888.	13.7	639
393	Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2014, 154, 1-12.	3.2	110
394	When biologics should be used in systemic lupus erythematosus?. <i>Presse Medicale</i> , 2014, 43, e181-e185.	1.9	5
395	Which dose of steroids and which cytotoxics for severe lupus?. <i>Presse Medicale</i> , 2014, 43, e157-e165.	1.9	3
396	Impact of Race and Ethnicity in the Course and Outcome of Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 433-454.	1.9	58

#	ARTICLE	IF	CITATIONS
398	Mycophenolate Mofetil as a Potential Therapeutic Option for Neuropsychiatric Lupus: A Case Report. <i>Proceedings of Singapore Healthcare</i> , 2014, 23, 320-324.	0.6	1
399	New therapeutic avenues in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 794-809.	3.3	11
400	Belimumab in systemic lupus erythematosus: a perspective review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 115-121.	2.7	18
401	New biological therapies in Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 783-793.	3.3	7
402	Biologic agents in the treatment of glomerulonephritides. <i>Nephrology</i> , 2015, 20, 767-787.	1.6	3
403	Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. <i>Health Economics (United Kingdom)</i> , 2015, 24, 1468-1482.	1.7	9
404	Lupus Nephritis in Asia: Clinical Features and Management. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 100-109.	2.5	67
405	How I diagnose and treat lupus. <i>Medicina Universitaria</i> , 2015, 17, 59-63.	0.1	0
406	A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings. <i>Clinical Therapeutics</i> , 2015, 37, 2852-2863.	2.5	12
407	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 143.	3.5	180
408	Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. <i>Arthritis Research and Therapy</i> , 2015, 17, 39.	3.5	55
409	Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease. <i>BMC Pulmonary Medicine</i> , 2015, 15, 110.	2.0	12
410	Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 162.	3.5	44
411	The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1858-1867.	5.6	16
412	Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. <i>Arthritis and Rheumatology</i> , 2015, 67, 2523-2535.	5.6	21
413	Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , 2015, 5, 561-571.	0.0	4
415	Biologic therapies in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 146-153.	1.9	11
416	Malignancies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2015, 27, 454-460.	4.3	74

#	ARTICLE	IF	CITATIONS
436	Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. <i>Arthritis Research and Therapy</i> , 2015, 17, 241.	3.5	40
437	Treat-to-target in lupus: what does the future hold?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 461-477.	0.3	4
438	Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 234-246.	2.7	5
440	Developing new evaluation methods in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 479-488.	0.3	1
441	Belimumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 195-204.	3.0	21
442	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 1-21.	0.7	3
443	Lymphocytes and Infection in Autoimmune Diseases. , 2015, , 109-131.		0
444	Infections and Systemic Lupus Erythematosus. , 2015, , 697-714.		2
445	Deficiency of the B Cell-Activating Factor Receptor Results in Limited CD169 ⁺ Macrophage Function during Viral Infection. <i>Journal of Virology</i> , 2015, 89, 4748-4759.	3.4	22
446	B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. <i>Current Opinion in Immunology</i> , 2015, 33, 70-77.	5.5	51
447	Evaluation of the immunomodulatory effect of melatonin on the T cell response in peripheral blood from systemic lupus erythematosus patients. <i>Journal of Pineal Research</i> , 2015, 58, 219-226.	7.4	51
448	Rituximab: the Lupus Journey. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 30-41.	1.4	16
449	Biologics for the treatment of systemic lupus erythematosus: current status and emerging therapies. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 109-116.	3.0	41
450	What is new in the management of rapidly progressive glomerulonephritis?. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 143-150.	2.9	39
451	Belimumab: Where Are We Three Years After FDA Approval?. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 42-50.	1.4	0
452	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	2.0	11
453	B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. <i>Blood Cancer Journal</i> , 2015, 5, e282-e282.	6.2	69
454	Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows. <i>Autoimmunity Reviews</i> , 2015, 14, 601-608.	5.8	52

#	ARTICLE	IF	CITATIONS
455	Immunopathology of chronic rhinosinusitis. <i>Allergology International</i> , 2015, 64, 121-130.	3.3	206
456	The development and assessment of biological treatments for children. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 379-394.	2.4	8
457	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1079-1086.	5.8	59
458	Current and future treatment options for cutaneous lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 777-786.	0.8	0
459	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2015, 43, 538-544.	0.4	2
460	Development and pharmacological validation of novel methods of B cell activation in rat whole blood. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 61-67.	0.7	1
461	Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells. <i>Arthritis and Rheumatology</i> , 2015, 67, 612-615.	5.6	6
462	Cytokines. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2243-2254.	4.5	111
463	Genetics and novel aspects of therapies in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1005-1018.	5.8	72
464	Pathogenesis of Renal Disease in Systemic Lupus Erythematosus—The Role of Autoantibodies and Lymphocytes Subset Abnormalities. <i>International Journal of Molecular Sciences</i> , 2015, 16, 7917-7931.	4.1	60
465	Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1119-1143.	3.1	16
466	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	17.8	14
467	Stem cell therapies for systemic lupus erythematosus: current progress and established evidence. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 763-769.	3.0	8
468	Pharmacotherapy for managing extraglandular symptoms of primary Sjögren's syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 125-139.	0.8	3
470	Neuropsychiatric lupus: a mosaic of clinical presentations. <i>BMC Medicine</i> , 2015, 13, 43.	5.5	142
471	Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. <i>Immunotherapy</i> , 2015, 7, 255-270.	2.0	6
472	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	3.4	88
473	Belimumab in systemic lupus erythematosus. <i>RMD Open</i> , 2015, 1, e000011-e000011.	3.8	20

#	ARTICLE	IF	CITATIONS
474	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	3.3	22
475	Lupus eritematoso sist�mico. <i>EMC - Aparato Locomotor</i> , 2015, 48, 1-17.	0.1	1
476	What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1093-1107.	3.0	3
477	Treatment of Myasthenia Gravis in the Aged. <i>Drugs and Aging</i> , 2015, 32, 689-697.	2.7	15
478	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. <i>Journal of Rheumatology</i> , 2015, 42, 2288-2295.	2.0	79
479	Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2015, 42, 2412-2418.	2.0	17
480	Role of B Cell�Activating Factor in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 706-718.	5.6	87
481	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , 2015, 2, e000104.	2.7	45
482	Treatment of systemic lupus erythematosus patients with the BAFF antagonist �ceptibody�blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	3.5	48
483	B-cell survival factors in autoimmune rheumatic disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 122-151.	2.7	27
484	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. <i>Current Rheumatology Reports</i> , 2015, 17, 65.	4.7	16
485	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , 2015, 42, 1401-1405.	2.0	7
486	Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1635-1645.	3.3	3
488	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
489	Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. <i>Seminars in Nephrology</i> , 2015, 35, 509-520.	1.6	24
491	Current role of rituximab in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 154-163.	1.9	53
492	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. <i>Rheumatology</i> , 2015, 54, 623-632.	1.9	19
494	Safety of off-label biologicals in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 243-251.	2.4	9

#	ARTICLE	IF	CITATIONS
495	High-risk pregnancy and the rheumatologist. <i>Rheumatology</i> , 2015, 54, 572-587.	1.9	66
496	Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 250-254.	2.3	37
497	Treatment of severe lupus nephritis: the new horizon. <i>Nature Reviews Nephrology</i> , 2015, 11, 46-61.	9.6	78
498	A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1667-1675.	0.9	135
499	Lupus Nephritis: From Pathogenesis to Targets for Biologic Treatment. <i>Nephron Clinical Practice</i> , 2015, 128, 224-231.	2.3	30
500	Biologic Therapy in Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 255-260.	2.3	14
501	'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 394-400.	0.7	4
502	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 526-531.	0.9	248
503	Glomerulonephritis – Do We Have Promising Role of Monoclonal Antibodies?. <i>Journal of Clinical & Experimental Nephrology</i> , 2016, 01, .	0.1	0
505	Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	2.2	24
506	TNF and TNFR Family Members and B Cell Activation. , 2016, , 259-268.		1
507	Systemic Glucocorticoids. , 2016, , 521-531.		3
508	New Treatments for Systemic Lupus Erythematosus. , 2016, , 551-557.		3
509	The Musculoskeletal System in Systemic Lupus Erythematosus. , 2016, , 325-332.		0
510	The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation. <i>Journal of Immunology Research</i> , 2016, 2016, 1-9.	2.2	3
511	Oxidative Stress in Systemic Lupus Erythematosus. , 2016, , 237-242.		0
512	Rheumatoid Rescue of Misfolded Cellular Proteins by MHC Class II Molecules. <i>Advances in Immunology</i> , 2016, 129, 1-23.	2.2	17
513	MRL Strains Have a BAFFR Mutation without Functional Consequence. <i>PLoS ONE</i> , 2016, 11, e0154518.	2.5	1

#	ARTICLE	IF	CITATIONS
514	Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 44-46.	0.6	0
515	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , 2016, 5, 9.	5.8	32
516	Immunomodulators in SLE: Clinical evidence and immunologic actions. <i>Journal of Autoimmunity</i> , 2016, 74, 73-84.	6.5	71
517	Editorial: A Stalemate in Lupus-Related End-Stage Renal Disease: Can We Do Better?. <i>Arthritis and Rheumatology</i> , 2016, 68, 1323-1326.	5.6	4
518	Rare Presentation of Lupus Myocarditis With Acute Heart Failure—A Case Report. <i>American Journal of Therapeutics</i> , 2016, 23, e1952-e1955.	0.9	7
519	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. <i>Journal of Autoimmunity</i> , 2016, 74, 94-105.	6.5	42
520	MEI-51 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for <i>Sle1</i> and Human CD19. <i>Arthritis and Rheumatology</i> , 2016, 68, 965-976.	5.6	21
521	Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. <i>Arthritis Care and Research</i> , 2016, 68, 534-543.	3.4	33
522	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	2.7	51
523	Other Biological Therapies for Pediatric Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2016, 11, 503-525.	0.1	1
524	Role of the cytokine BAFF in autoimmune diseases: Physiopathology and therapeutic targets. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2016, 23, 177-194.	0.0	5
525	From BLISS to ILLUMINATE studies: “Blys repetita placenta”: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e10-e10.	0.9	2
527	BUDGET IMPACT ANALYSIS OF BELIMUMAB IN TREATING SYSTEMIC LUPUS ERYTHEMATOSUS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 348-354.	0.5	9
528	It hasn't gone away: the problem of glucocorticoid use in lupus remains. <i>Rheumatology</i> , 2016, 56, kew406.	1.9	43
529	Systemic lupus erythematosus biomarkers: the challenging quest. <i>Rheumatology</i> , 2016, 56, kew407.	1.9	47
530	Update on clinical trials in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2016, 28, 477-487.	4.3	51
531	Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. <i>Lupus Science and Medicine</i> , 2016, 3, e000180.	2.7	31
532	Overview of pathophysiology and treatment of human lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 460-467.	4.3	14

#	ARTICLE	IF	CITATIONS
536	Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. <i>Cell</i> , 2016, 165, 551-565.	28.9	524
537	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. <i>Lupus</i> , 2016, 25, 1440-1447.	1.6	19
538	The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. <i>Lupus</i> , 2016, 25, 1597-1601.	1.6	24
539	Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis. <i>Journal of Immunology</i> , 2016, 197, 58-67.	0.8	44
540	The safety of pharmacological treatment options for lupus nephritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1041-1054.	2.4	7
541	Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. <i>Clinical Rheumatology</i> , 2016, 35, 1719-1723.	2.2	27
542	Recent advances and current state of immunotherapy in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 927-939.	3.1	15
543	Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 723-733.	3.1	12
544	Efficacy and Safety of Belimumab Plus Standard Therapy in Patients With Systemic Lupus Erythematosus: A Meta-analysis. <i>Clinical Therapeutics</i> , 2016, 38, 1134-1140.	2.5	15
545	Connective Tissue Disease. <i>Rare Diseases of the Immune System</i> , 2016, , .	0.1	2
546	Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. <i>Lupus</i> , 2016, 25, 699-709.	1.6	82
547	Joint Involvement in Systemic Lupus Erythematosus. <i>Rare Diseases of the Immune System</i> , 2016, , 61-76.	0.1	0
548	Elevated BLYS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. <i>Lupus</i> , 2016, 25, 346-354.	1.6	37
549	Innovative Therapies in Systemic Lupus Erythematosus. <i>Rare Diseases of the Immune System</i> , 2016, , 239-261.	0.1	0
551	The problems and pitfalls in systemic lupus erythematosus drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 525-527.	5.0	7
553	Beyond pan-B-cell-directed therapy " new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	8.0	69
554	B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3407-3424.	2.3	32
555	Membranous Lupus Nephritis: The Same, But Different. <i>American Journal of Kidney Diseases</i> , 2016, 68, 954-966.	1.9	22

#	ARTICLE	IF	CITATIONS
556	The skin in autoimmune diseasesâ€™Unmet needs. <i>Autoimmunity Reviews</i> , 2016, 15, 948-954.	5.8	17
557	Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody. <i>Molecular Immunology</i> , 2016, 77, 141-147.	2.2	0
558	Why targeted therapies are necessary for systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1070-1079.	1.6	19
559	Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1086-1096.	1.6	21
560	A critical review of clinical trials in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1122-1140.	1.6	56
561	T-cell-directed therapies in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1080-1085.	1.6	4
562	Patient-reported outcomes in lupus clinical trials with biologics. <i>Lupus</i> , 2016, 25, 1111-1121.	1.6	25
563	Cumulative Corticosteroid Dose Over Fiftyâ€™Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. <i>Arthritis and Rheumatology</i> , 2016, 68, 2184-2192.	5.6	44
564	Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 208-215.	1.6	23
565	Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1587-1596.	1.6	14
566	B cell-independent contribution of BAFF to murine autoimmune disease. <i>Clinical Immunology</i> , 2016, 172, 111-116.	3.2	7
567	New insights into the immunopathogenesis of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2016, 12, 716-730.	8.0	909
568	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. <i>Inflammation and Regeneration</i> , 2016, 36, 6.	3.7	42
569	Management of Lupus Nephritis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 225-238.	1.4	2
570	Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1225-1238.	3.1	9
571	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.2	7
572	The role of B cells and autoantibodies in neuropsychiatric lupus. <i>Autoimmunity Reviews</i> , 2016, 15, 890-895.	5.8	32
573	Phage display-derived human antibodies in clinical development and therapy. <i>MAbs</i> , 2016, 8, 1177-1194.	5.2	263

#	ARTICLE	IF	CITATIONS
574	IgA nephropathy. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16001.	30.5	322
575	Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 37-44.	2.5	21
576	Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation. <i>Journal of Immunology</i> , 2016, 197, 4529-4534.	0.8	41
577	Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. <i>Arthritis Research and Therapy</i> , 2016, 18, 243.	3.5	9
578	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2431-2448.	1.8	37
579	Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years. <i>Current Rheumatology Reports</i> , 2016, 18, 73.	4.7	62
580	First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. <i>Rheumatology and Therapy</i> , 2016, 3, 271-290.	2.3	60
581	Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis. <i>Scientific Reports</i> , 2016, 5, 17685.	3.3	39
582	Complex disease=complex trial? Lessons from a successful trial of anti-IFN γ in SLE. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1899-1901.	0.9	2
583	Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2016, 3, e000146.	2.7	57
584	Pin1-Targeted Therapy for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 2503-2513.	5.6	22
585	Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. <i>Immunological Reviews</i> , 2016, 269, 130-144.	6.0	50
586	Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. <i>Lupus</i> , 2016, 25, 1448-1455.	1.6	30
587	Update on Biologic Therapies for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2016, 18, 44.	4.7	11
588	Autophagy: controlling cell fate in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2016, 12, 517-531.	8.0	106
589	Advances in the treatment of cutaneous lupus erythematosus. <i>Lupus</i> , 2016, 25, 830-837.	1.6	26
590	Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1109-1121.	3.0	14
591	T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. <i>European Journal of Immunology</i> , 2016, 46, 281-290.	2.9	121

#	ARTICLE	IF	CITATIONS
592	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
593	A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon- λ) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 196-202.	0.9	302
596	Safety of treatments for primary Sjögren's syndrome. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 513-524.	2.4	14
597	Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. <i>Lupus Science and Medicine</i> , 2016, 3, e000118.	2.7	98
598	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2016, 67, 102-110.	6.5	68
599	From BILAG to BILAG-based combined lupus assessment—30 years on. <i>Rheumatology</i> , 2016, 55, 1357-1363.	1.9	21
600	Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 775-786.	3.0	8
602	Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. <i>Paediatric Drugs</i> , 2016, 18, 181-195.	3.1	19
603	Interfering with baffled B cells at the lupus tollway: Promises, successes, and failed expectations. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1325-1333.	2.9	8
604	The dynamic evolution of rheumatology in Korea. <i>Nature Reviews Rheumatology</i> , 2016, 12, 183-189.	8.0	12
605	Why, why, why de-lupus (does so badly in clinical trials). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 95-98.	3.0	22
606	Malignancy in Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 13-20.	1.4	1
607	Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. <i>Clinical Therapeutics</i> , 2016, 38, 610-624.	2.5	38
608	Emerging therapies in systemic lupus erythematosus: from clinical trial to the real life. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 681-694.	3.1	4
609	Biologics for the treatment of autoimmune renal diseases. <i>Nature Reviews Nephrology</i> , 2016, 12, 217-231.	9.6	45
610	Infection and Lupus: Which Causes Which?. <i>Current Rheumatology Reports</i> , 2016, 18, 13.	4.7	69
611	What Causes Lupus Flares?. <i>Current Rheumatology Reports</i> , 2016, 18, 14.	4.7	42
612	A liposomal steroid nano-drug for treating systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1209-1216.	1.6	30

#	ARTICLE	IF	CITATIONS
613	Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant. <i>Clinical Rheumatology</i> , 2016, 35, 1649-1653.	2.2	8
614	Targeting BAFF/BlyS in lupus: is the glass half-full or half-empty?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 321-322.	0.9	11
615	Towards new avenues in the management of lupus glomerulonephritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 221-234.	8.0	64
616	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 859-867.	3.4	15
617	Pharmacologic management of neuropsychiatric lupus. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 103-108.	3.1	6
618	Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 582-592.	1.6	108
619	Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 323-331.	0.9	191
620	Use of biologics in SLE: a review of the evidence from a clinical perspective. <i>Rheumatology</i> , 2016, 55, 775-779.	1.9	10
621	Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 332-340.	0.9	187
622	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , 2016, 61, 65-82.	4.0	29
623	CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 217-233.	6.5	6
624	Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. <i>Lupus</i> , 2017, 26, 27-37.	1.6	32
625	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	3.5	8
627	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-two-Week Randomized, Double-blind, Placebo-controlled Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1016-1027.	5.6	287
628	La investigación sobre tratamientos biológicos en el lupus eritematoso sistémico. <i>Medicina Clínica</i> , 2017, 148, 67-68.	0.6	0
629	Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2017, 69, 1313-1324.	5.6	94
630	Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. <i>Autoimmunity Reviews</i> , 2017, 16, 287-293.	5.8	60
631	Systemic lupus erythematosus. <i>Clinical Medicine</i> , 2017, 17, 78-83.	1.9	44

#	ARTICLE	IF	CITATIONS
632	Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. <i>International Reviews of Immunology</i> , 2017, 36, 3-19.	3.3	144
633	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 343-351.	5.8	80
634	BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. <i>Journal of Immunology</i> , 2017, 198, 2602-2611.	0.8	59
635	Novel Treatments in Lupus. <i>Current Rheumatology Reports</i> , 2017, 19, 10.	4.7	4
636	Biologic Therapies for Autoimmune and Connective Tissue Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 283-299.	1.9	24
637	Expanding the B Cell-Centric View of Systemic Lupus Erythematosus. <i>Trends in Immunology</i> , 2017, 38, 373-382.	6.8	40
638	Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). <i>Expert Review of Clinical Immunology</i> , 2017, 13, 623-633.	3.0	44
639	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
640	The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 1257-1266.	5.6	36
642	Altered B cell signalling in autoimmunity. <i>Nature Reviews Immunology</i> , 2017, 17, 421-436.	22.7	243
643	Pathways leading to an immunological disease: systemic lupus erythematosus. <i>Rheumatology</i> , 2017, 56, i55-i66.	1.9	124
644	Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. <i>Lupus</i> , 2017, 26, 1072-1081.	1.6	36
645	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. <i>Current Treatment Options in Neurology</i> , 2017, 19, 19.	1.8	5
646	B Cell Biology. , 2017, , 97-119.		1
647	Broad Concepts in Management of Systemic Lupus Erythematosus. <i>Mayo Clinic Proceedings</i> , 2017, 92, 744-761.	3.0	14
648	Belimumab in the management of systemic lupus erythematosus – an update. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 901-908.	3.1	12
649	Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>New England Journal of Medicine</i> , 2017, 376, 1615-1626.	27.0	301
650	Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 677-692.	3.0	22

#	ARTICLE	IF	CITATIONS
651	BAFF emerges from the genetic shadows. <i>Nature Reviews Rheumatology</i> , 2017, 13, 456-457.	8.0	4
652	Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned. <i>Lupus</i> , 2017, 26, 909-916.	1.6	7
653	Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 756-760.	1.9	8
654	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. <i>Trends in Molecular Medicine</i> , 2017, 23, 615-635.	6.7	328
656	Treatment of lupus nephritis: current paradigms and emerging strategies. <i>Current Opinion in Rheumatology</i> , 2017, 29, 241-247.	4.3	30
657	Research on biological therapies in systemic lupus erythematosus. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 67-68.	0.2	0
658	Belimumab for the treatment of recalcitrant cutaneous lupus. <i>Lupus</i> , 2017, 26, 857-864.	1.6	47
659	Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 75-85.	2.7	34
660	Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSERVE Canada Study. <i>Rheumatology International</i> , 2017, 37, 865-873.	3.0	55
662	Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. <i>Immunotherapy</i> , 2017, 9, 57-70.	2.0	10
663	Biothérapies dans le lupus systémique: de nouvelles cibles. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 23-30.	0.0	0
664	Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 207-219.	1.4	1
665	Treat to target, remission and low disease activity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 342-350.	3.3	24
666	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2071-2074.	0.9	89
667	Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. <i>Journal of Immunology</i> , 2017, 199, 3757-3770.	0.8	26
668	Immunoabsorption in Autoimmune Diseases Affecting the Kidney. <i>Seminars in Nephrology</i> , 2017, 37, 478-487.	1.6	23
669	Anti-Rheumatic Therapy and Comorbidity. , 2017, , 345-380.		0
670	Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 925-938.	3.0	12

#	ARTICLE	IF	CITATIONS
671	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017, 16, 1119-1124.	5.8	13
672	The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5+CD1dhiFcγ3RIIbhi Regulatory B-Cell Subset in Lupus. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2532-2543.	0.7	23
673	Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. <i>Journal of Immunology</i> , 2017, 199, 2388-2407.	0.8	48
674	Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. <i>Clinical and Experimental Immunology</i> , 2017, 190, 187-200.	2.6	24
675	The Cutaneous Spectrum of Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 291-305.	6.5	83
676	Investigational drugs in systemic vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1049-1061.	4.1	5
677	Efectos del belimumab en pacientes colombianos con lupus eritematoso sistémico, un estudio prospectivo observacional. <i>Revista Colombiana De Reumatología</i> , 2017, 24, 159-163.	0.1	0
678	Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice. <i>Clinical Therapeutics</i> , 2017, 39, 1811-1826.	2.5	14
679	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 951-962.	3.0	29
680	Novel Immunomodulatory Treatment Modalities. , 2017, , 177-192.		0
681	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. <i>Lupus Science and Medicine</i> , 2017, 4, e000173.	2.7	25
682	A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice. <i>Scientific Reports</i> , 2017, 7, 16642.	3.3	33
683	Anti-IL-39 (IL-23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus-like mice. <i>Molecular Medicine Reports</i> , 2018, 17, 1660-1666.	2.4	17
684	Role of interferons in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 415-428.	3.3	99
685	Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155. <i>Growth Factors</i> , 2017, 35, 49-60.	1.7	23
686	Medicine Based Evidence for Individualized Decision Making: Case Study of Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2017, 130, 1290-1297.e6.	1.5	11
687	Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1479-1506.e45.	2.5	12
688	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	1.9	2

#	ARTICLE	IF	CITATIONS
689	Musculoskeletal manifestations of systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2017, 29, 486-492.	4.3	29
690	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.8	1
691	Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2017, 187, 376-382.	2.6	31
692	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 667-676.	3.0	14
693	S2k guideline for treatment of cutaneous lupus erythematosus “ guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 389-404.	2.4	117
694	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. <i>Arthritis and Rheumatology</i> , 2017, 69, 643-654.	5.6	58
695	Systemic lupus erythematosus: still a challenge for physicians. <i>Journal of Internal Medicine</i> , 2017, 281, 52-64.	6.0	61
696	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. <i>Modern Rheumatology</i> , 2017, 27, 284-291.	1.8	7
697	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
698	New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 788-790.	3.4	28
699	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 115-123.	3.4	107
700	Editorial: Interferon-targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?. <i>Arthritis and Rheumatology</i> , 2017, 69, 245-248.	5.6	1
701	Discovery of novel BTK inhibitors with carboxylic acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1471-1477.	2.2	17
702	Biotherapies in systemic lupus erythematosus: New targets. <i>Joint Bone Spine</i> , 2017, 84, 267-274.	1.6	14
703	Effects of belimumab in Colombian patients with systemic lupus erythematosus; a prospective observational study. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2017, 24, 159-163.	0.0	0
704	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. <i>Lupus Science and Medicine</i> , 2017, 4, e000239.	2.7	82
705	Long-term efficacy and safety of antitumour necrosis factor alpha treatment in lupus: an open-label study of 15 patients. <i>RMD Open</i> , 2017, 3, e000555.	3.8	20
706	Juvenile-onset systemic lupus erythematosus (jSLE) “ Pathophysiological concepts and treatment options. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 488-504.	3.3	62

#	ARTICLE	IF	CITATIONS
707	Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 747-757.	4.3	28
708	Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2017, Volume 7, 31-45.	1.3	5
709	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 294.	4.8	56
710	Systemic lupus erythematosus: an update. <i>Medical Journal of Australia</i> , 2017, 206, 215-220.	1.7	38
711	HM71224, a selective Brutonâ€™s tyrosine kinase inhibitor, attenuates the development of murine lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 211.	3.5	44
712	The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus. <i>Journal of Rheumatic Diseases</i> , 2017, 24, 65.	1.1	0
713	The Roles of the TNF-Family Member B-Cell Activation Factor Belonging to the TNF-Family (BAFF) in Autoimmunity. , 0, , .		1
714	Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1779-1787.	1.8	3
715	Treatment of Systemic Lupus Erythematosus. , 2017, , 1368-1388.e5.		3
716	Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. <i>F1000Research</i> , 2017, 6, 874.	1.6	21
717	Brief Report: A Randomized, Doubleâ€Blind, Parallelâ€Group, Placeboâ€Controlled, Multipleâ€Dose Study to Evaluate <scp>AMG</scp> 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1071-1076.	5.6	47
718	Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 331-343.	6.5	34
719	Low disease activityâ€™irrespective of serologic status at baselineâ€™associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	3.4	59
720	Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE. <i>Lupus</i> , 2018, 27, 955-962.	1.6	18
721	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	2.7	62
722	Efficacy and Safety of Subcutaneous Belimumab in Antiâ€™Doubleâ€™Stranded <scp>DNA</scp>â€™Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 1256-1264.	5.6	49
723	An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 581-593.	1.4	4
725	Genetic variants in mRNA untranslated regions. <i>Wiley Interdisciplinary Reviews RNA</i> , 2018, 9, e1474.	6.4	118

#	ARTICLE	IF	CITATIONS
726	BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. <i>Nature Communications</i> , 2018, 9, 1200.	12.8	31
727	Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. <i>Neurology</i> , 2018, 90, e1425-e1434.	1.1	86
728	Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. <i>Arthritis and Rheumatology</i> , 2018, 70, 1450-1458.	5.6	18
729	Treatment of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 141-154.		0
730	Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse. <i>Scientific Reports</i> , 2018, 8, 1308.	3.3	19
731	Belimumab: A Review in Systemic Lupus Erythematosus. <i>Drugs</i> , 2018, 78, 355-366.	10.9	95
732	Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 868-877.	5.6	63
733	The interplay between tuberculosis and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2018, 30, 395-402.	4.3	35
734	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018, 28, 986-992.	1.8	50
735	Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 221-239.	3.4	43
737	Biomimetic Nanosponges for Treating Antibody-Mediated Autoimmune Diseases. <i>Bioconjugate Chemistry</i> , 2018, 29, 870-877.	3.6	12
738	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	6.1	39
740	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
741	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 355-363.	0.9	196
742	Systemic and Biologic Agents for Lupus Erythematosus. , 2018, , 377-390.		0
743	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
744	New Trials in Lupus and where Are we Going. <i>Current Rheumatology Reports</i> , 2018, 20, 34.	4.7	10
745	Emerging role of semaphorin-3A in autoimmune diseases. <i>Inflammopharmacology</i> , 2018, 26, 655-665.	3.9	22

#	ARTICLE	IF	CITATIONS
746	Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. <i>Advances in Therapy</i> , 2018, 35, 439-456.	2.9	35
747	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 883-889.	0.9	107
748	Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. <i>Lancet, The</i> , 2018, 391, 1186-1196.	13.7	290
749	Peli1 negatively regulates noncanonical NF- κ B signaling to restrain systemic lupus erythematosus. <i>Nature Communications</i> , 2018, 9, 1136.	12.8	55
750	Epratuzumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 245-258.	3.0	31
752	Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. <i>Lupus</i> , 2018, 27, 112-119.	1.6	17
753	Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. <i>Lupus</i> , 2018, 27, 243-256.	1.6	44
754	Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 290-302.	1.6	21
755	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018, 57, 125-133.	1.9	15
756	Profile of BAFF and its receptors TM expression in lupus nephritis is associated with pathological classes. <i>Lupus</i> , 2018, 27, 708-715.	1.6	22
757	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 266-276.	5.6	184
758	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018, 86, 1-8.	6.5	86
759	Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus. <i>Patient</i> , 2018, 11, 119-129.	2.7	25
760	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 352-367.	6.5	75
761	Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2018, 57, 717-728.	3.5	17
763	An era of biological treatment in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 1-3.	2.2	13
764	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	5.2	313
765	Immune response patterns in non ^o communicable inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 692-703.	2.4	110

#	ARTICLE	IF	CITATIONS
766	Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight, 2018, 3, .	5.0	44
767	Mortality of patients with systemic lupus erythematosus admitted to the intensive care unit â€“ A retrospective single-center study. Best Practice and Research in Clinical Rheumatology, 2018, 32, 701-709.	3.3	16
768	Engaging African ancestry participants in SLE clinical trials. Lupus Science and Medicine, 2018, 5, e000297.	2.7	20
769	SLE, An Overlooked Disease: Possibilities for Early Rescue by Early Diagnosis. , 2018, , .		0
770	Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leukemia Research, 2018, 75, 45-49.	0.8	32
771	Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab. Frontiers in Immunology, 2018, 9, 2698.	4.8	32
772	Update on Lupus Nephritis for GPs. Lupus, 2018, 27, 11-14.	1.6	2
773	Biologics in Inflammatory Immune-mediated Systemic Diseases. Current Pharmaceutical Biotechnology, 2018, 18, 1008-1016.	1.6	17
774	Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. Lupus Science and Medicine, 2018, 5, e000288.	2.7	11
775	Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction. Patient Preference and Adherence, 2018, Volume 12, 2475-2479.	1.8	8
777	Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Current Opinion in Rheumatology, 2018, 30, 664-673.	4.3	52
778	Ustekinumab: a promising new drug for SLE?. Lancet, The, 2018, 392, 1284-1286.	13.7	6
779	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Review of Clinical Immunology, 2018, 14, 915-931.	3.0	45
781	Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cells. Nature Communications, 2018, 9, 4369.	12.8	94
782	Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. Lupus, 2018, 27, 2029-2040.	1.6	16
783	BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. Oncotarget, 2018, 9, 3292-3302.	1.8	6
784	Glucocorticoid-induced osteoporosis in systemic lupus erythematosus. Rheumatology Practice and Research, 2018, 3, 205990211880251.	0.0	0
785	Pharmacological potentiation of the efferent vagus nerve attenuates blood pressure and renal injury in a murine model of systemic lupus erythematosus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2018, 315, R1261-R1271.	1.8	32

#	ARTICLE	IF	CITATIONS
786	Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells. <i>Journal of Immunology</i> , 2018, 201, 3258-3268.	0.8	19
787	The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. <i>Journal of Autoimmunity</i> , 2018, 95, 179-190.	6.5	31
788	The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review. <i>Lupus</i> , 2018, 27, 2135-2145.	1.6	13
789	Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. <i>BMC Nephrology</i> , 2018, 19, 276.	1.8	11
790	Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1926-1935.	1.6	14
791	Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1609-1618.	1.9	35
792	Comparison of Plasma Cytokine Levels before and after Treatment with Rituximab in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus-Associated Polyautoimmunity. <i>Revista Universitas Medica</i> , 2018, 59, 1-16.	0.1	6
793	A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1489-1498.	1.6	23
794	Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2018, 8, 8195.	3.3	17
795	B-cell activating factor and related genetic variants in lupus related atherosclerosis. <i>Journal of Autoimmunity</i> , 2018, 92, 87-92.	6.5	51
796	Individual Drugs in Rheumatology and the Risk of Infection. , 2018, , 445-464.		0
797	Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases. <i>Current Pharmacology Reports</i> , 2018, 4, 358-366.	3.0	1
798	Poly IC pretreatment suppresses B cell-mediated lupus-like autoimmunity through induction of Peli1. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 862-868.	2.0	9
799	Lupus Nephritis: Current Treatment Paradigm and Unmet Needs. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 105-113.	0.8	16
800	Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 656.	4.8	8
801	Targeting B Cells and Plasma Cells in Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 835.	4.8	204
802	Neurological Disease in Lupus: Toward a Personalized Medicine Approach. <i>Frontiers in Immunology</i> , 2018, 9, 1146.	4.8	36
803	Analysis of Serum Interleukin (IL)-1 β and IL-18 in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1250.	4.8	89

#	ARTICLE	IF	CITATIONS
804	BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. <i>Science Advances</i> , 2018, 4, eaas9944.	10.3	98
805	Essential and Optional Drugs for Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, , 77-96.	0.1	0
806	Recent advances in the management of systemic lupus erythematosus. <i>F1000Research</i> , 2018, 7, 970.	1.6	23
807	Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. <i>BMC Nephrology</i> , 2018, 19, 54.	1.8	21
808	Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes. <i>Arthritis Research and Therapy</i> , 2018, 20, 13.	3.5	34
809	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. <i>Nature Reviews Rheumatology</i> , 2018, 14, 580-591.	8.0	61
810	Subcutaneous belimumab in the treatment of systemic lupus erythematosus. <i>Immunotherapy</i> , 2018, 10, 1163-1173.	2.0	3
811	Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 765-777.	5.0	12
812	The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. <i>Autoimmunity Reviews</i> , 2018, 17, 781-790.	5.8	59
813	Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 391, 2619-2630.	13.7	78
814	Immunological investigations empower transplant drug trials. <i>Lancet, The</i> , 2018, 391, 2578-2579.	13.7	3
815	Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases. <i>Journal of Internal Medicine</i> , 2018, 284, 228-239.	6.0	1
816	TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression. <i>Kidney International</i> , 2018, 94, 728-740.	5.2	14
817	Time to change the primary outcome of lupus trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 581-582.	0.9	9
818	The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 811-821.	3.4	27
819	Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , 2019, 29, 452-460.	1.8	13
821	Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus. <i>Modern Rheumatology</i> , 2019, 29, 60-69.	1.8	12
822	B-cell therapy in lupus nephritis: an overview. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 22-29.	0.7	35

#	ARTICLE	IF	CITATIONS
823	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. Health Information and Libraries Journal, 2019, 36, 318-340.	2.5	3
824	Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. BioMed Research International, 2019, 2019, 1-17.	1.9	41
825	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmunity Reviews, 2019, 18, 102372.	5.8	14
826	Efficacy of BAFF in Monitoring Treatment Response in Early Vietnamese Systemic Sclerosis Patients. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 264-268.	0.2	3
827	Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. Lupus, 2019, 28, 1167-1173.	1.6	1
828	No interactions between heparin and atacicept, an antagonist of B cell survival cytokines. British Journal of Pharmacology, 2019, 176, 4019-4033.	5.4	8
829	Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects. Frontiers in Immunology, 2019, 10, 1601.	4.8	33
830	<p>Management of refractory lupus nephritis: challenges and solutions</p>. Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 179-188.	1.6	17
831	APRIL Induces a Novel Subset of IgA+ Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1. Frontiers in Immunology, 2019, 10, 1368.	4.8	63
832	Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scandinavian Journal of Rheumatology, 2019, 48, 469-473.	1.1	22
833	Hypersensitivity reactions to biologics used in rheumatology. Expert Review of Clinical Immunology, 2019, 15, 1263-1271.	3.0	8
834	SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. Scientific Reports, 2019, 9, 14433.	3.3	20
836	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	3.9	250
837	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e163-e173.	3.9	16
838	Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial. Lupus, 2019, 28, 1628-1639.	1.6	19
839	Elevated serum Bâ€cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease. Journal of Dermatology, 2019, 46, 1190-1196.	1.2	17
840	BAFF inhibition in SLEâ€™s tolerance restored?. Immunological Reviews, 2019, 292, 102-119.	6.0	38
841	The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opinion on Drug Safety, 2019, 18, 1133-1144.	2.4	26

#	ARTICLE	IF	CITATIONS
842	10 most important contemporary challenges in the management of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000303.	2.7	55
843	Ultrasensitive serum interferon- γ quantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1669-1676.	0.9	59
844	Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987430.	2.7	14
845	T Cell- and B Cell-Mediated Pathology in Chronic Graft-Versus-Host Disease. , 2019, , 251-273.		0
846	Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 629-633.	0.9	53
847	Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 1-7.	1.2	19
848	Therapeutic effects of a novel BAFF blocker on arthritis. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 19.	17.1	18
849	Inflammation, Monoclonal Antibodies and Depression: Joining the Dots. <i>Drug Safety</i> , 2019, 42, 811-812.	3.2	1
850	Assessing joint inflammation—a way forward for SLE trials?. <i>Rheumatology</i> , 2019, 58, 1327-1328.	1.9	0
851	Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. <i>Drugs</i> , 2019, 79, 1199-1215.	10.9	27
852	Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. <i>Nature Communications</i> , 2019, 10, 2498.	12.8	100
853	New therapies for systemic lupus erythematosus — past imperfect, future tense. <i>Nature Reviews Rheumatology</i> , 2019, 15, 403-412.	8.0	122
854	IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2477-2487.	0.7	29
855	Case 17-2019: A 44-Year-Old Man with Joint Pain, Weight Loss, and Chest Pain. <i>New England Journal of Medicine</i> , 2019, 380, 2157-2167.	27.0	1
856	Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease — frontiers and horizons. , 2019, 202, 40-52.		41
857	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 2170-2176.	1.9	26
858	Management strategies and future directions for systemic lupus erythematosus in adults. <i>Lancet</i> , The, 2019, 393, 2332-2343.	13.7	319
859	Novel paradigms in systemic lupus erythematosus. <i>Lancet</i> , The, 2019, 393, 2344-2358.	13.7	363

#	ARTICLE	IF	CITATIONS
860	Development of tibatuzumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. <i>MABs</i> , 2019, 11, 1175-1190.	5.2	31
861	Excessive miR-152-3p Results in Increased BAFF Expression in SLE B-Cells by Inhibiting the KLF5 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1127.	4.8	23
862	The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2019, 8, 826.	2.4	11
863	Current Clinical Trials in Pemphigus and Pemphigoid. <i>Frontiers in Immunology</i> , 2019, 10, 978.	4.8	63
864	<p>Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1535-1543.	4.3	47
865	How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-215650.	0.9	5
866	Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics. <i>Pharmaceutics</i> , 2019, 11, 211.	4.5	34
867	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1670-1680.	5.6	22
868	Cytokines and Chemokines. , 2019, , 127-141.		2
869	Selenium supplementation suppresses immunological and serological features of lupus in B6.<i>Sle1b</i> mice. <i>Autoimmunity</i> , 2019, 52, 57-68.	2.6	14
870	Innate Immune Cells' Contribution to Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 772.	4.8	127
871	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 693-700.	3.0	31
872	Current Insights Into Systemic Lupus Erythematosus. , 2019, , 475-482.		0
873	Analysis of serum B cell–activating factor from the tumor necrosis factor family (<scp>BAFF</scp>) and its soluble receptors in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , 2019, 8, e01047.	3.8	25
875	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019, 9, e025687.	1.9	81
876	Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge. <i>Cytokine and Growth Factor Reviews</i> , 2019, 46, 54-65.	7.2	4
877	Belimumab in kidney transplantation. <i>Lancet, The</i> , 2019, 393, 874-875.	13.7	0
878	The therapeutic challenge of late antibody–mediated kidney allograft rejection. <i>Transplant International</i> , 2019, 32, 775-788.	1.6	89

#	ARTICLE	IF	CITATIONS
879	B cell checkpoints in autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2019, 15, 303-315.	8.0	62
880	The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus. <i>Cells</i> , 2019, 8, 323.	4.1	23
881	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
882	The role of BAFF and APRIL in rheumatoid arthritis. <i>Journal of Cellular Physiology</i> , 2019, 234, 17050-17063.	4.1	49
883	A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. <i>Kidney International</i> , 2019, 96, 104-116.	5.2	41
884	Real-world evidence in rheumatic diseases: relevance and lessons learnt. <i>Rheumatology International</i> , 2019, 39, 403-416.	3.0	22
885	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	5.6	74
886	Recomendaciones SER sobre la utilización de fármacos biológicos en el síndrome de Sjögren primario. <i>Reumatología Clínica</i> , 2019, 15, 315-326.	0.5	5
887	Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e553-e578.	1.6	89
888	Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. <i>Current Opinion in Rheumatology</i> , 2019, 31, 175-184.	4.3	20
889	Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus. <i>Cells</i> , 2019, 8, 140.	4.1	34
890	SLE clinical trials: impact of missing data on estimating treatment effects. <i>Lupus Science and Medicine</i> , 2019, 6, e000348.	2.7	7
891	1. Systemischer Lupus erythematosus. , 2019, , 1-54.		0
892	Steroid sparing effect: an essential element in assessing therapeutic efficacy in SLE: response to "Time to change the primary outcome of lupus trials"™ by Houssiau. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216113.	0.9	5
893	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019, 9, e032569.	1.9	35
894	Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. <i>Lupus Science and Medicine</i> , 2019, 6, e000365.	2.7	23
895	Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 285.	3.7	45
896	SER recommendations on the use of biological drugs in primary Sjögren's syndrome. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 315-326.	0.3	2

#	ARTICLE	IF	CITATIONS
897	Moving Forward With Biologics in Lupus Nephritis. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 338-350.	1.4	7
898	Treat to Target in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 537-548.	1.9	13
899	Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	2.2	9
900	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 259.	3.5	16
901	<p>Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections<p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1889-1894.	1.8	5
902	B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritisâ€™Role in Pathogenesis and Effect of Immunosuppressive Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6231.	4.1	88
903	Pathogenesis and treatment of autoimmune rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2019, 31, 307-315.	4.3	31
904	Cytokine targets in lupus nephritis: Current and future prospects. <i>Clinical Immunology</i> , 2019, 206, 42-52.	3.2	18
905	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 157-168.	3.1	19
906	B Cells and Generation of Antibodies. , 2019, , 101-115.		1
907	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes. , 2019, , 355-365.		4
908	The Musculoskeletal System and Bone Metabolism. , 2019, , 407-417.		1
909	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
910	Systemic Glucocorticoid Therapy for SLE. , 2019, , 661-672.		0
911	Targeted Therapies in SLE. , 2019, , 710-718.		0
912	Target Therapy in SLE. <i>Autoimmunity Reviews</i> , 2019, 18, 21-24.	5.8	12
913	Targets of monoclonal antibodies for immunological diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 293-304.	6.3	4
914	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , 2019, 96, 1-13.	6.5	405

#	ARTICLE	IF	CITATIONS
915	Humanised effector-null Fc γ RIIA antibody inhibits immune complex-mediated proinflammatory responses. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 228-237.	0.9	25
916	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 729-735.	0.9	39
917	Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1006-1007.	0.9	9
918	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 372-379.	0.9	59
919	B cell alterations during BAFF inhibition with belimumab in SLE. <i>EBioMedicine</i> , 2019, 40, 517-527.	6.1	88
920	Depletion of BAFF cytokine exacerbates infection in <i>Pseudomonas aeruginosa</i> infected mice. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 349-356.	0.7	6
921	The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. <i>Physiological Reviews</i> , 2019, 99, 115-160.	28.8	275
922	Use of synthetic and biologic DMARDs during pregnancy. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 27-39.	3.0	7
923	Response to: "Clinical evidence guidelines in systemic lupus erythematosus: reevaluation" by Scheinberg. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e120-e120.	0.9	1
924	Long-term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. <i>Arthritis Care and Research</i> , 2019, 71, 829-838.	3.4	32
925	New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019, 15, 30-48.	8.0	118
926	Regulatory and effector B cells: Friends or foes?. <i>Journal of Dermatological Science</i> , 2019, 93, 2-7.	1.9	84
927	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. <i>Joint Bone Spine</i> , 2019, 86, 429-436.	1.6	24
928	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 304-312.	1.9	28
929	Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients. <i>Cellular and Molecular Immunology</i> , 2019, 16, 367-379.	10.5	40
930	Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , 2020, 30, 313-320.	1.8	11
932	Treatment of Autoimmune Disease: Established Therapies. , 2020, , 1415-1435.		0
933	Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 1-9.	2.1	31

#	ARTICLE	IF	CITATIONS
934	Membranous glomerulonephritis: a step forward in B-cell targeting therapy?. Nephrology Dialysis Transplantation, 2020, 35, 549-551.	0.7	3
935	Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology, 2020, 59, 281-291.	1.9	55
936	Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrology Dialysis Transplantation, 2020, 35, 599-606.	0.7	45
937	Autoimmune Diseases in the Kidney. , 2020, , 1355-1366.		1
938	Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF. Arthritis and Rheumatology, 2020, 72, 292-302.	5.6	6
939	Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus. Cells, 2020, 9, 72.	4.1	26
940	Anti-BAFF Therapy: A New Tool to Target B Cells in Antibody-mediated Rejection?. Transplantation, 2020, 104, e3-e4.	1.0	2
941	From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. Lancet Rheumatology, The, 2020, 2, e50-e62.	3.9	17
942	The pathological role of B cells in systemic lupus erythematosus: From basic research to clinical. Autoimmunity, 2020, 53, 56-64.	2.6	24
943	B cells targeting therapy in the management of systemic lupus erythematosus. Immunological Medicine, 2020, 43, 16-35.	2.6	21
944	Animal Models: Systemic Autoimmune Diseases. , 2020, , 533-551.		1
945	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
946	B Cell Activation and B Cell Tolerance. , 2020, , 171-187.		1
947	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. , 2020, , 283-312.		0
948	Passive Monoclonal and Polyclonal Antibody Therapies. , 2020, , 251-348.		9
949	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase <sc>II</sc> Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 761-768.	5.6	38
950	Anti-BAFF Treatment Interferes With Humoral Responses in a Model of Renal Transplantation in Rats. Transplantation, 2020, 104, e16-e22.	1.0	12
951	IFN-Î± kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Annals of the Rheumatic Diseases, 2020, 79, 347-355.	0.9	67

#	ARTICLE	IF	CITATIONS
952	Biologic therapies for systemic lupus erythematosus: where are we now?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 597-608.	4.3	8
953	Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 609-616.	4.3	12
954	Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries. <i>American Journal of Human Genetics</i> , 2020, 107, 864-881.	6.2	23
956	Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 2725.	3.7	7
957	Treg Enhancing Therapies to Treat Autoimmune Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7015.	4.1	116
958	Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095333.	2.7	23
959	A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1091-1108.	0.8	8
960	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	3.4	8
961	Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. <i>Lupus Science and Medicine</i> , 2020, 7, e000412.	2.7	11
962	Treat-to-Target bei systemischem Lupus erythematosus. <i>Karger Kompass Autoimmun</i> , 2020, 2, 45-52.	0.0	0
963	The design, synthesis and evaluation of 2-aminobenzoxazole analogues as potent and orally efficacious ChemR23 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115622.	3.0	7
965	Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4975.	4.1	14
966	Immunomodulatory Therapies for Interstitial Cystitis/Bladder Pain Syndrome. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 186-191.	0.5	0
967	Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBServe Studies. <i>Rheumatology and Therapy</i> , 2020, 7, 949-965.	2.3	30
968	Systemic lupus erythematosus and infections. <i>Reumatismo</i> , 2020, 72, 154-169.	0.9	13
969	Targeting B cells for inflammatory bowel disease treatment: back to the future. <i>Current Opinion in Pharmacology</i> , 2020, 55, 90-98.	3.5	34
970	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020, 7, 553075.	2.6	7
971	Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1151-1162.	4.1	6

#	ARTICLE	IF	CITATIONS
972	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1340-1348.	0.9	106
973	Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies. <i>Experimental Dermatology</i> , 2020, 29, 1123-1132.	2.9	6
974	Mapping systemic lupus erythematosus heterogeneity at the single-cell level. <i>Nature Immunology</i> , 2020, 21, 1094-1106.	14.5	212
975	Effects of AS2819899, a novel selective PI3K γ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model. <i>International Immunopharmacology</i> , 2020, 87, 106764.	3.8	2
976	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , 2020, 59, 3622-3632.	1.9	39
977	Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSERVE study in Argentina. <i>Lupus</i> , 2020, 29, 1385-1396.	1.6	13
978	Review article: experimental therapies in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1134-1149.	3.7	12
979	Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials. <i>Lupus Science and Medicine</i> , 2020, 7, e000429.	2.7	26
980	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. <i>Lupus</i> , 2020, 29, 1902-1913.	1.6	14
981	Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. <i>Lupus Science and Medicine</i> , 2020, 7, e000350.	2.7	5
982	01â€¦Understanding and treating SLE: a new era is dawning. , 2020, , .		0
983	02â€¦Debate: a majority of lupus patients (will) need a biologic!. , 2020, , .		0
984	String of successful trials in SLE: have we cracked the code?. <i>Lupus Science and Medicine</i> , 2020, 7, e000380.	2.7	6
985	Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. <i>Frontiers in Medicine</i> , 2020, 7, 498.	2.6	15
986	Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. <i>Lupus Science and Medicine</i> , 2020, 7, e000373.	2.7	25
987	Lupus nephritis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 7.	30.5	416
988	New Therapeutic Horizons for Gravesâ€™ Hyperthyroidism. <i>Endocrine Reviews</i> , 2020, 41, 873-884.	20.1	56
989	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. <i>New England Journal of Medicine</i> , 2020, 383, 1117-1128.	27.0	506

#	ARTICLE	IF	CITATIONS
990	Targeting co-stimulatory molecules in autoimmune disease. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 860-883.	46.4	109
992	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 447-453.	0.7	3
993	Treatment targets in SLE: remission and low disease activity state. <i>Rheumatology</i> , 2020, 59, v19-v28.	1.9	26
994	Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases—Implications for Therapeutic Approaches. <i>Cells</i> , 2020, 9, 2627.	4.1	24
995	Manifestaciones cutáneas del lupus eritematoso. <i>EMC - Dermatología</i> , 2020, 54, 1-17.	0.1	0
996	Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA. <i>Lupus Science and Medicine</i> , 2020, 7, e000357.	2.7	14
997	The role of baseline BlyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 102.	3.5	23
998	Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. <i>Rheumatology and Therapy</i> , 2020, 7, 433-446.	2.3	100
999	The history of lupus throughout the ages. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1361-1369.	1.2	12
1000	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3463.	4.1	26
1001	Critical Illness and the Frailty Syndrome: Mechanisms and Potential Therapeutic Targets. <i>Anesthesia and Analgesia</i> , 2020, 130, 1545-1555.	2.2	16
1002	Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lupus Science and Medicine</i> , 2020, 7, e000383.	2.7	4
1003	Are lupus animal models useful for understanding and developing new therapies for human SLE?. <i>Journal of Autoimmunity</i> , 2020, 112, 102490.	6.5	13
1004	Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. <i>Lupus</i> , 2020, 29, 1011-1020.	1.6	79
1005	Rituximab use as induction therapy for lupus nephritis: a systematic review. <i>Lupus</i> , 2020, 29, 892-912.	1.6	15
1006	<p>Bruton&™s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 105-110.	5.8	29
1007	Infections Related to Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 161-178.	5.1	10
1008	Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2020, 9, 1813.	2.4	7

#	ARTICLE	IF	CITATIONS
1009	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	68
1010	Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus. <i>Frontiers in Medicine</i> , 2020, 7, 222.	2.6	17
1011	The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 682.	2.8	9
1012	Biosimilars. <i>Lupus</i> , 2020, 29, 525-532.	1.6	3
1013	State-of-the-Art treatment of systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 465-471.	1.9	85
1014	Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e210-e216.	3.9	36
1016	Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. <i>Immunotherapy</i> , 2020, 12, 275-286.	2.0	16
1017	Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. <i>Frontiers in Medicine</i> , 2020, 7, 303.	2.6	59
1018	<p>Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2503-2513.	4.3	17
1019	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , 2020, 7, 316.	2.6	50
1020	Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments. <i>Pharmacological Research</i> , 2020, 160, 105054.	7.1	9
1021	Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis. <i>Clinical Rheumatology</i> , 2020, 39, 3653-3659.	2.2	8
1022	Novel therapeutic opportunities afforded by plasma cell biology in transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1984-1991.	4.7	10
1023	Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy. <i>Obstetrics and Gynecology</i> , 2020, 135, 723-727.	2.4	5
1024	Unraveling the mysteries of plasma cells. <i>Advances in Immunology</i> , 2020, 146, 57-107.	2.2	18
1025	Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). <i>Journal of Nephrology</i> , 2020, 33, 1019-1025.	2.0	26
1026	Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. <i>Rheumatology and Therapy</i> , 2020, 7, 191-200.	2.3	5
1027	Biological and Immunosuppressive Respiratory Therapy in Pregnancy. , 2020, , 200-209.		1

#	ARTICLE	IF	CITATIONS
1028	Promotion of T Regulatory Cells in Mice by B Cells and BAFF. <i>Journal of Immunology</i> , 2020, 204, 2416-2428.	0.8	12
1029	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020, 32, 215-227.	4.3	8
1030	Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1258-F1270.	2.7	5
1031	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	1.2	129
1032	The musculoskeletal system in SLE. , 2021, , 361-370.		0
1033	The nervous system in systemic lupus erythematosus. , 2021, , 469-478.		0
1034	New treatments of systemic lupus erythematosus. , 2021, , 629-639.		0
1035	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 67-73.	2.0	28
1036	Which is the best SLE activity index for clinical trials?. <i>Modern Rheumatology</i> , 2021, 31, 20-28.	1.8	24
1037	Measuring disease activity. , 2021, , 29-35.		0
1038	B cells in SLE. , 2021, , 131-138.		1
1040	Metabolic control of lupus pathogenesis: central role for activation of the mechanistic target of rapamycin. , 2021, , 267-276.		0
1041	Systemic glucocorticoids. , 2021, , 597-609.		0
1042	Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. <i>Clinical Rheumatology</i> , 2021, 40, 581-590.	2.2	10
1043	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	1.9	3
1044	Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 255-264.	5.6	16
1045	Kidney outcomes for children with lupus nephritis. <i>Pediatric Nephrology</i> , 2021, 36, 1377-1385.	1.7	53
1046	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. <i>Trends in Molecular Medicine</i> , 2021, 27, 152-171.	6.7	34

#	ARTICLE	IF	CITATIONS
1047	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.7	12
1048	Anti-IFN α 1R Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 519-528.	3.1	9
1049	Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. <i>Cytotherapy</i> , 2021, 23, 37-45.	0.7	2
1050	Update in the diagnosis and management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 14-25.	0.9	312
1051	Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. <i>Biologics</i> , 2021, 69, 1-14.	1.4	13
1052	Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 622-633.	1.6	6
1053	Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 609-617.	0.7	18
1054	B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). <i>Autoimmunity Reviews</i> , 2021, 20, 102736.	5.8	86
1055	An updated advance of autoantibodies in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2021, 20, 102743.	5.8	87
1056	B cell depletion therapies in autoimmune disease: advances and mechanistic insights. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 179-199.	46.4	296
1057	Targeted delivery in scleroderma fibrosis. <i>Autoimmunity Reviews</i> , 2021, 20, 102730.	5.8	10
1058	Belimumab in systemic lupus erythematosus: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 1-12.	0.6	3
1059	Regulation of neuroinflammation by B cells and plasma cells. <i>Immunological Reviews</i> , 2021, 299, 45-60.	6.0	19
1060	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. <i>Modern Rheumatology</i> , 2021, 31, 1-12.	1.8	52
1061	Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1260-1272.	1.9	15
1062	Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. <i>Lupus</i> , 2021, 30, 702-706.	1.6	13
1063	Pipeline therapies and future drug development. , 2021, , 661-671.		0
1064	Mechanisms of Secretory Dysfunction in Autoimmune Sjögren's Syndrome. , 2021, , 33-58.		0

#	ARTICLE	IF	CITATIONS
1065	Lupus Nephritis. , 2021, , 1-34.		0
1066	Challenges of systemic lupus clinical trials. , 2021, , 673-682.		0
1067	New developments in systemic lupus erythematosus. Rheumatology, 2021, 60, vi21-vi28.	1.9	16
1068	Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE. Rheumatology, 2021, 60, 4205-4217.	1.9	11
1069	EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. Rheumatology, 2021, 60, 4703-4716.	1.9	12
1070	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Therapeutics and Clinical Risk Management, 2021, Volume 17, 39-54.	2.0	38
1071	Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fc γ 3 receptor IIb in non-autoimmune-prone and SLE-prone mice. Journal of Translational Autoimmunity, 2021, 4, 100075.	4.0	9
1072	The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS ONE, 2021, 16, e0244439.	2.5	17
1073	Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab. BMJ Case Reports, 2021, 14, e237549.	0.5	5
1074	Metrics and Outcomes of SLE Clinical Trials. , 2021, , 371-390.		0
1078	Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000438.	2.7	2
1079	Biologic therapies for the treatment of systemic lupus erythematosus. Journal of the Korean Medical Association, 2021, 64, 109-115.	0.3	1
1080	Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials. Rheumatology, 2021, 60, 5390-5396.	1.9	1
1081	Monoclonal Antibodies: A Prospective and Retrospective View. Current Medicinal Chemistry, 2021, 28, 435-471.	2.4	8
1082	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Science and Medicine, 2021, 8, e000459.	2.7	7
1083	Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatology, The, 2021, 3, e122-e130.	3.9	21
1084	Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie, 2021, 75, 293-303.	0.1	3
1085	Systemic lupus erythematosus: diverting progress to chase rare side effects?. Lancet Rheumatology, The, 2021, 3, e87-e88.	3.9	0

#	ARTICLE	IF	CITATIONS
1086	Anticuerpos monoclonales y el tratamiento del lupus eritematoso sistémico. Tecnología En Marcha, 0, , .	0.1	0
1087	Belimumab for systemic lupus erythematosus. The Cochrane Library, 2021, 2021, CD010668.	2.8	27
1088	B Cell Aberrance in Lupus: the Ringleader and the Solution. Clinical Reviews in Allergy and Immunology, 2022, 62, 301-323.	6.5	12
1089	Management of Lupus Nephritis. Journal of Clinical Medicine, 2021, 10, 670.	2.4	16
1090	The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. Rheumatology and Therapy, 2021, 8, 375-393.	2.3	21
1091	Interventions for cutaneous disease in systemic lupus erythematosus. The Cochrane Library, 2021, 2021, CD007478.	2.8	12
1092	Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. Expert Opinion on Drug Safety, 2021, 20, 523-536.	2.4	2
1093	Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology, 2021, , .	1.9	1
1094	Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review. Reumatología Clínica, 2021, 17, 170-174.	0.5	8
1095	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	3.9	26
1096	EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice. Frontiers in Immunology, 2021, 12, 653989.	4.8	17
1097	Stem Cell Therapy as a Treatment for Autoimmune Disease—Updates in Lupus, Scleroderma, and Multiple Sclerosis. Current Allergy and Asthma Reports, 2021, 21, 22.	5.3	9
1098	Outcome Scores in Pediatric Rheumatology. Current Rheumatology Reports, 2021, 23, 23.	4.7	5
1099	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Research and Therapy, 2021, 23, 70.	3.5	12
1100	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. Arthritis Care and Research, 2022, 74, 1623-1630.	3.4	3
1101	Belimumab: a step forward in the treatment of systemic lupus erythematosus. Expert Opinion on Biological Therapy, 2021, 21, 563-573.	3.1	9
1103	Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review. Reumatología Clínica (English Edition), 2021, 17, 170-174.	0.3	1
1104	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For musculoskeletal Lupus longitudinal multicentre study. Rheumatology, 2021, 60, 5194-5204.	1.9	16

#	ARTICLE	IF	CITATIONS
1105	Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 651249.	2.6	27
1106	Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 33.	1.9	1
1107	Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis. <i>Blood Purification</i> , 2022, 51, 182-188.	1.8	9
1108	B cell-activating factor modulates the factor VIII immune response in hemophilia A. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	10
1109	Lupus Pneumonitis Therapy Masks Coronavirus (COVID-19). <i>Case Reports in Rheumatology</i> , 2021, 2021, 1-4.	0.6	1
1110	Transcriptomic studies of systemic lupus erythematosus. <i>Inflammation and Regeneration</i> , 2021, 41, 11.	3.7	8
1111	Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 272-284.	1.4	0
1112	A Consensus for the Management of Systemic Lupus Erythematosus in Asia. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021, 21, 1-6.	0.4	2
1113	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
1114	Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. <i>Journal of Autoimmunity</i> , 2021, 119, 102615.	6.5	37
1115	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 666971.	3.5	5
1116	Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	26
1117	Tackling Chronic Kidney Transplant Rejection: Challenges and Promises. <i>Frontiers in Immunology</i> , 2021, 12, 661643.	4.8	45
1118	Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics. <i>American Journal of Kidney Diseases</i> , 2021, 77, 984-987.	1.9	2
1119	Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 112-123.	5.6	47
1120	Treatment Update in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 513-530.	1.9	6
1121	Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	27
1122	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 415-426.	1.9	4

#	ARTICLE	IF	CITATIONS
1123	TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice. <i>European Journal of Immunology</i> , 2021, 51, 2225-2236.	2.9	1
1124	Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus. <i>Clinical Therapeutics</i> , 2021, 43, 1320-1335.	2.5	4
1125	Bispecific antibodies: A guide to model informed drug discovery and development. <i>Heliyon</i> , 2021, 7, e07649.	3.2	3
1126	Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. <i>Journal of the American Heart Association</i> , 2021, 10, e018555.	3.7	17
1128	Systemic Lupus Erythematosus Research: A Bibliometric Analysis over a 50-Year Period. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7095.	2.6	40
1129	Increasing numbers of CD19 ⁺ CD24 ^{high} CD38 ^{high} regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia. <i>International Journal of Hematology</i> , 2021, 114, 580-590.	1.6	3
1130	The role of reversible and irreversible covalent chemistry in targeted protein degradation. <i>Cell Chemical Biology</i> , 2021, 28, 952-968.	5.2	51
1131	Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 601-611.	1.6	3
1132	Possible activation of effector B cells during drug-induced hypersensitivity syndrome. <i>Journal of Cutaneous Immunology and Allergy</i> , 2021, 4, 166-169.	0.3	0
1133	Blood Genomics Identifies Three Subtypes of Systemic Lupus Erythematosus: IFN-High , NE-High , and Mixed . <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	3.0	5
1134	Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. <i>Frontiers in Medicine</i> , 2021, 8, 707104.	2.6	11
1135	10 Years of belimumab experience: What have we learnt?. <i>Lupus</i> , 2021, 30, 1705-1721.	1.6	53
1136	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. <i>RMD Open</i> , 2021, 7, e001629.	3.8	17
1137	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021, 73, 1243-1249.	3.4	13
1138	Safety updates in novel therapeutics for pediatric rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 403-408.	4.3	1
1139	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). <i>Lupus Science and Medicine</i> , 2021, 8, e000513.	2.7	8
1140	Systemic lupus erythematosus: a clinical update. <i>Internal Medicine Journal</i> , 2021, 51, 1219-1228.	0.8	2
1141	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1835-1846.	5.6	59

#	ARTICLE	IF	CITATIONS
1142	Novel Therapeutic Interventions in Systemic Lupus Erythematosus. , 0, , .		0
1143	B Cells in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2021, 47, 395-413.	1.9	12
1144	Prospects for the use of belimumab in lupus nephritis. Sovremennaya Revmatologiya, 2021, 15, 94-100.	0.5	0
1145	Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	88
1146	Dysregulated translational factors and epigenetic regulations orchestrate in B cells contributing to autoimmune diseases. International Reviews of Immunology, 2023, 42, 1-25.	3.3	3
1147	B cells as target for immunotherapy in rheumatic diseases – current status. Immunology Letters, 2021, 236, 12-19.	2.5	10
1148	Innovative Trials and New Opportunities in SLE. Rheumatic Disease Clinics of North America, 2021, 47, 481-499.	1.9	2
1149	Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatology, The, 2021, 3, e595-e603.	3.9	13
1150	Systemic Lupus Erythematosus Pregnancy. , 0, , .		1
1151	Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study. Pediatric Nephrology, 2022, 37, 377-383.	1.7	5
1152	Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nature Reviews Rheumatology, 2021, 17, 585-595.	8.0	99
1153	Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study. Rheumatology and Therapy, 2021, 8, 1711-1724.	2.3	1
1154	Signaling networks in B cell development and related therapeutic strategies. Journal of Leukocyte Biology, 2022, 111, 877-891.	3.3	2
1155	The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clinical Reviews in Allergy and Immunology, 2022, 63, 152-165.	6.5	12
1156	Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 367-383.	1.0	12
1157	Review article: targeting the B cell activation system in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2021, 54, 902-922.	3.7	4
1158	Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. IScience, 2021, 24, 103076.	4.1	6
1160	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open, 2021, 7, e001747.	3.8	10

#	ARTICLE	IF	CITATIONS
1161	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	13.7	8
1162	Is There a Place for Chimeric Antigen Receptorâ€T Cells in the Treatment of Chronic Autoimmune RheumaticADiseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	5.6	28
1163	Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. <i>Nature Reviews Rheumatology</i> , 2021, 17, 651-664.	8.0	60
1164	BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization. <i>Transplant Immunology</i> , 2021, 69, 101465.	1.2	7
1166	Immunosuppressive therapy in SLE. , 2021, , 623-659.		0
1167	Kidney disease. , 2021, , 471-502.		0
1168	Pathology of Systemic Lupus Erythematosus: The Challenges Ahead. <i>Methods in Molecular Biology</i> , 2014, 1134, 1-16.	0.9	26
1169	Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases. <i>Methods in Molecular Biology</i> , 2016, 1371, 143-155.	0.9	4
1170	Multiparameter Flow Cytometry and Bioanalytics for B Cell Profiling in Systemic Lupus Erythematosus. <i>Methods in Molecular Biology</i> , 2012, 900, 109-134.	0.9	22
1171	Understanding B Cell Biology. <i>Milestones in Drug Therapy</i> , 2014, , 11-35.	0.1	5
1172	Systemic Lupus Erythematosus: Direct B-Cell Blocking. <i>Milestones in Drug Therapy</i> , 2014, , 65-78.	0.1	1
1173	Stem Cell Therapy in the Treatment of Rheumatic Diseases and Application in the Treatment of Systemic Lupus Erythematosus. , 2017, , 167-198.		2
1174	Neue Arzneimittel 2011. , 2012, , 43-126.		1
1176	Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline. <i>BioDrugs</i> , 2020, 34, 133-147.	4.6	25
1179	Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1070-1076.	0.9	40
1180	Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. <i>Lupus Science and Medicine</i> , 2018, 5, e000253.	2.7	18
1181	Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis. <i>Lupus Science and Medicine</i> , 2020, 7, e000435.	2.7	18
1182	Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	15

#	ARTICLE	IF	CITATIONS
1183	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight, 2020, 5, .	5.0	47
1184	BAFF-ling autoantibodies. Journal of Clinical Investigation, 2013, 123, 5006-5008.	8.2	6
1185	Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. Journal of Clinical Investigation, 2016, 126, 4289-4302.	8.2	46
1186	Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. Journal of Clinical Investigation, 2017, 127, 2492-2504.	8.2	167
1187	A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Research, 2020, 9, 905.	1.6	16
1188	Active Chronic Sarcoidosis is Characterized by Increased Transitional Blood B Cells, Increased IL-10-Producing Regulatory B Cells and High BAFF Levels. PLoS ONE, 2012, 7, e43588.	2.5	78
1189	The Effect of BAFF Inhibition on Autoreactive B-Cell Selection in Murine Systemic Lupus Erythematosus. Molecular Medicine, 2016, 22, 173-182.	4.4	21
1190	Therapeutic Antibodies by Phage Display. Current Pharmaceutical Design, 2017, 22, 6538-6559.	1.9	27
1191	Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review. Current Pharmaceutical Design, 2020, 26, 2668-2675.	1.9	8
1192	Biologics for ANCA-Associated Vasculitis. Inflammation and Allergy: Drug Targets, 2014, 13, 275-287.	1.8	6
1193	The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatology Journal, 2012, 6, 245-258.	0.2	82
1195	Interferon targeted therapies in systemic lupus erythematosus. Mediterranean Journal of Rheumatology, 2017, 28, 13-19.	0.8	4
1196	Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrologia, 2014, 34, 388-97.	0.4	8
1197	Belimumab in systemic lupus erythematosus. Indian Journal of Dermatology, 2016, 61, 550.	0.3	15
1198	Juvenile systemic lupus erythematosus: A diagnostic dilemma. Journal of Natural Science, Biology and Medicine, 2011, 2, 229.	1.0	4
1199	Current status of lupus nephritis. Indian Journal of Medical Research, 2017, 145, 167-178.	1.0	17
1200	Treatment of SLE and Secondary Sjogrenâ€™s Syndrome with Belimumab. Journal of Immunobiology, 2016, 01, .	0.3	1
1201	Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative. European Journal of Rheumatology, 2016, 3, 13-19.	0.6	11

#	ARTICLE	IF	CITATIONS
1202	Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2016, 54, 914-922.	0.6	15
1204	Biological therapies in rheumatic diseases. <i>Clinica Terapeutica</i> , 2013, 164, e413-28.	0.3	37
1205	Circulating plasmablasts in children with steroid-sensitive nephrotic syndrome. <i>Pediatric Nephrology</i> , 2021, , 1.	1.7	3
1206	Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e526.	4.0	10
1207	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. <i>Rheumatology</i> , 2022, 61, 1341-1353.	1.9	4
1208	Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11327.	4.1	20
1209	The lupus nephritis management renaissance. <i>Kidney International</i> , 2022, 101, 242-255.	5.2	40
1210	B-Cell Targeted Therapeutics in Systemic Lupus Erythematosus: From Paradox to Synergy?. <i>Annals of Internal Medicine</i> , 2021, 174, 1747-1748.	3.9	2
1211	Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials. <i>Lupus Science and Medicine</i> , 2021, 8, e000534.	2.7	7
1212	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2021, 174, 1647-1657.	3.9	64
1213	Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. <i>Drugs in R and D</i> , 2021, 21, 407-417.	2.2	2
1215	Experimental Therapies in Sjögren's Syndrome. , 2011, , 599-616.		0
1216	The Emerging Role of Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus. , 0, , .		0
1217	Kollagenosen. , 2012, , 103-131.		0
1218	New and Emerging Therapies. , 2012, , 223-228.		0
1220	The Role of B-Cells and B-Cell Targeted Therapies in Lupus Nephritis. , 0, , .		0
1221	Developing novel drugs for systemic lupus erythematosus. Lessons learned from the belimumab trials. <i>Reviews in Health Care</i> , 2012, 3, 209-222.	0.1	0
1222	Les nouveauté's physiopathologiques à la base de la révolution thérapeutique des biothérapies dans les rhumatismes inflammatoires. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 1261-1278.	0.0	0

#	ARTICLE	IF	CITATIONS
1223	Refractory Autoimmune Hemolytic Anemia in a Pediatric SLE Patient Treated with Belimumab. <i>Annals of Paediatric Rheumatology</i> , 2013, 2, 38.	0.0	0
1224	Comment je traite une atteinte articulaire r��fractaire aux AINS ?. , 2013, , 311-314.		0
1226	Molecular targeted therapy as new options for childhood kidney diseases. <i>Japanese Journal of Pediatric Nephrology</i> , 2013, 26, 43-51.	0.0	0
1227	Biologic modifiers of inflammatory diseases. , 2013, , 1131-1142.		0
1228	Targeted Therapies in Systemic Lupus Erythematosus: A State-of-the Art Review. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 01, .	1.5	0
1229	New treatment strategy including biological agents in patients with systemic lupus erythematosus. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 482-490.	0.4	4
1230	Safety of B-Cell Targeted Therapies. <i>Milestones in Drug Therapy</i> , 2014, , 259-276.	0.1	0
1231	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. <i>Milestones in Drug Therapy</i> , 2014, , 79-95.	0.1	0
1232	Skin in Systemic Lupus Erythematosus. , 2014, , 1075-1088.		2
1233	Systemic Lupus Erythematosus, <i>Clinical Trials</i> . , 2014, , 1156-1161.		0
1234	Systemic Lupus Erythematosus, Antiphospholipid Syndrome and the Kidney. , 2014, , 235-247.		0
1235	Belimumab. <i>Pharma-Kritik (discontinued)</i> , 2014, 36, .	0.0	0
1236	New possibilities of pharmacotherapy for systemic lupus erythematosus: A place of belimumab. <i>Sovremennaya Revmatologiya</i> , 2014, , 4.	0.5	0
1237	Autoimmunerkrankungen. , 2015, , 577-607.		0
1238	Renal Involvement in Children with Systemic Lupus Erythematosus. , 2015, , 1-45.		0
1239	Management of nonrenal and non��central nervous system lupus. , 2015, , 1099-1106.		0
1240	Belimumab: Present and future. <i>Journal of Autoimmune Disorders</i> , 2015, 1, .	0.2	0
1242	Oral manifestations of connective tissue disease and novel therapeutic approaches. <i>Dermatology Online Journal</i> , 2015, 21, .	0.5	4

#	ARTICLE	IF	CITATIONS
1243	Assessing disease activity and outcome in systemic lupus erythematosus. , 2015, , 1093-1098.		0
1244	IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE. Nauchno-Prakticheskaya Revmatologiya, 2015, , 78.	1.0	1
1245	Proliferative nephritis in childhood-onset systemic lupus erythematosus: current therapeutic approaches and future perspectives. F1000Research, 0, 4, 128.	1.6	0
1246	ADVANCES IN THERAPY FOR CUTANEOUS LUPUS ERYTHEMATOSUS. , 2015, , 237-256.		0
1247	ADVANCES IN THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS. , 2015, , 129-164.		0
1248	Morbimortalidad cardiopulmonar en pacientes con lupus eritematoso sistÃ©mico. Memorias Del Instituto De Investigaciones En Ciencias De La Salud, 2015, 13, 127-138.	0.1	0
1249	Renal Involvement in Children with Systemic Lupus Erythematosus. , 2016, , 1449-1488.		0
1250	Measuring Disease Activity. , 2016, , 23-29.		1
1251	Clinical and laboratory manifstations in Systemic Lupus Erythematosus. Memorias Del Instituto De Investigaciones En Ciencias De La Salud, 2016, 14, 94-104.	0.1	2
1252	Kollagenosen. , 2017, , 75-96.		0
1253	Lupus erythematoses. , 2017, , 1-18.		0
1255	Treatments. , 2018, , 85-107.		0
1256	Therapies in late-stage clinical development. , 2018, , 109-120.		0
1257	Lupus erythematoses. , 2018, , 937-953.		1
1259	Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus. Farmakoekonomika, 2018, 11, 23-37.	1.2	0
1260	BAFF. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2019, 33, 244-245.	0.2	0
1261	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2019, 31, 87.	0.8	2
1262	Prospects for anti-BLyS treatment of systemic lupus erythematosus. Meditsinskiy Sovet, 2019, , 92-95.	0.5	0

#	ARTICLE	IF	CITATIONS
1264	According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 496-510.	1.0	3
1266	Treatment of systemic lupus erythematosus. Australian Prescriber, 2020, 43, 85-90.	1.0	8
1267	Treatment of Systemic Lupus Erythematosus. Korean Journal of Medicine, 2020, 95, 162-169.	0.3	2
1269	Developments in immunosuppression. Current Opinion in Organ Transplantation, 2021, 26, 91-96.	1.6	9
1270	The dawn of a new era of therapies in systemic lupus erythematosus. Rheumatology and Immunology Research, 2020, 1, 31-37.	0.8	3
1271	Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2673-2683.	5.7	15
1274	Systemic lupus erythematosus and related disorders. , 2020, , 4499-4513.		0
1275	Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA. Kidney Medicine, 2021, 3, 889-892.	2.0	1
1276	Specific nanotherapeutics for highly efficient diagnosis and treatment of systemic lupus erythematosus. Chemical Engineering Journal, 2022, 436, 133095.	12.7	7
1277	Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells, 2021, 10, 3017.	4.1	63
1278	Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus. Sovremennaya Revmatologiya, 2020, 14, 31-38.	0.5	1
1279	Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus. P and T, 2012, 37, 212-26.	0.9	12
1280	Immune surveillance and lymphoid malignancy in immunocompromised host. American Journal of Blood Research, 2013, 3, 91-101.	0.6	3
1281	Down-regulation of nectin-4 inhibits apoptosis in systemic lupus erythematosus (SLE) through targeting Bcl-2/Bax pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 10915-21.	0.5	1
1282	Serum B cell activating factor (BAFF) and sarcoidosis activity. Archives of Rheumatology, 2021, 36, 72-79.	0.9	0
1283	The combined detection of autoantibody characteristics in systemic lupus erythematosus. American Journal of Translational Research (discontinued), 2021, 13, 7242-7248.	0.0	0
1284	A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus. Value in Health Regional Issues, 2022, 27, 32-40.	1.2	1
1285	Discovery of a novel IgG ² and Fcγ ³ R1IB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. International Immunopharmacology, 2021, 101, 108343.	3.8	0

#	ARTICLE	IF	CITATIONS
1286	B cell-activating factor and its targeted therapy in autoimmune diseases. <i>Cytokine and Growth Factor Reviews</i> , 2022, 64, 57-70.	7.2	16
1289	Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 56, 116587.	3.0	1
1292	Non-infective cystitis secondary to benralizumab immunotherapy. <i>BMJ Case Reports</i> , 2022, 15, e244733.	0.5	2
1294	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 133-145.	8.0	193
1295	Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3777-3791.	1.9	4
1296	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 146-157.	8.0	55
1297	The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review. <i>Lupus</i> , 2022, 31, 287-296.	1.6	4
1298	Extrapolation as a Default Strategy in Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 883-894.	1.6	9
1299	Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000638.	2.7	4
1300	Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Autoimmunity Reviews</i> , 2022, 21, 103032.	5.8	1
1302	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, , .	3.0	5
1303	Efficacy and safety of belimumab in the treatment of systemic lupus erythematosus: A meta-analysis. <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.6	0
1304	Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE. <i>Lupus Science and Medicine</i> , 2022, 9, e000499.	2.7	8
1305	Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4979-5005.	2.3	5
1307	Synthesis and biological and physico-chemical characterization of glycodendrimers and oligopeptides for the treatment of systemic lupus erythematosus. <i>Nanoscale</i> , 2022, 14, 4654-4670.	5.6	3
1309	A glimpse into the future of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	2.7	14
1310	Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. <i>ACR Open Rheumatology</i> , 2022, 4, 486-491.	2.1	23
1311	Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2505.	4.1	21

#	ARTICLE	IF	CITATIONS
1312	Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature. <i>Cureus</i> , 2022, 14, e22540.	0.5	0
1313	The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. <i>Arthritis Research and Therapy</i> , 2022, 24, 46.	3.5	7
1314	A Current Review of Systemic Lupus Erythematosus Treatment Using Monoclonal Antibodies. <i>Current Biotechnology</i> , 2022, 11, 27-31.	0.4	1
1315	Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 843880.	2.8	12
1316	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	2.7	18
1317	Animal models of systemic lupus erythematosus and their applications in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 489-500.	5.0	1
1318	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. <i>Journal of Investigative Dermatology</i> , 2022, 142, 811-822.	0.7	5
1319	BAFF rs9514828 gene polymorphism and the risk of the development of inhibitors in children with severe haemophilia A. <i>Haemophilia</i> , 2022, 28, 472-479.	2.1	1
1320	Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. <i>Lupus</i> , 2022, 31, 424-432.	1.6	12
1321	Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Lupus</i> , 2022, 31, 666-673.	1.6	3
1322	Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 4752-4762.	1.9	15
1323	New Treatment Options in Lupus Nephritis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 11.	2.3	3
1324	A New IMiD for Systemic Lupus Erythematosus â€” Tempering Our Excitement. <i>New England Journal of Medicine</i> , 2022, 386, 1085-1086.	27.0	1
1325	Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2022, 18, 286-300.	8.0	18
1326	Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. <i>Frontiers in Immunology</i> , 2022, 13, 796508.	4.8	7
1327	Novel treatment options in rituximab-resistant membranous nephropathy patients. <i>International Immunopharmacology</i> , 2022, 107, 108635.	3.8	5
1328	Approach to Highly Sensitized Kidney Transplant Candidates and a Positive Crossmatch. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 587-595.	1.4	2
1329	Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. <i>Modern Rheumatology</i> , 2023, 33, 122-133.	1.8	2

#	ARTICLE	IF	CITATIONS
1330	Mechanism of Action and Efficacy of Immunosuppressors in Lupus Nephritis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 441-458.	1.8	6
1331	LncRNA Expression Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets. <i>Frontiers in Immunology</i> , 2021, 12, 792884.	4.8	19
1332	Increased gene expression of B cell-activating factor of tumor necrosis factor family, in remitting antineutrophil cytoplasmic antibody-associated vasculitis patients. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 218-227.	1.9	4
1333	Reduced expression of hematopoietic progenitor kinase 1 in T follicular helper cells causes autoimmunity of systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 28-38.	1.6	2
1334	B Lineage Cells in ANCA-Associated Vasculitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 387.	4.1	11
1335	Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. <i>RMD Open</i> , 2022, 8, e001669.	3.8	4
1336	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	3.4	9
1337	The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 103098.	5.8	9
1350	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
1352	Recent advances in the treatment of systemic lupus erythematosus with belimumab in children. <i>Chinese Journal of Contemporary Pediatrics</i> , 2021, 23, 1069-1074.	0.2	1
1354	A Review of Lupus Nephritis. <i>journal of applied laboratory medicine, The</i> , 2022, 7, 1450-1467.	1.3	9
1355	Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2022, 9, 852162.	2.6	4
1356	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 765-777.	1.4	14
1357	Successful treatment of bullous lupus with corticosteroids and belimumab: A case report. <i>Modern Rheumatology Case Reports</i> , 2023, 7, 52-56.	0.7	1
1359	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology, The</i> , 2022, 4, e441-e449.	3.9	17
1360	Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and meta-analysis of randomised controlled trials. <i>International Immunopharmacology</i> , 2022, 109, 108811.	3.8	5
1362	Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2072143.	3.3	6
1363	Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity. <i>Lupus Science and Medicine</i> , 2022, 9, e000657.	2.7	2

#	ARTICLE	IF	CITATIONS
1364	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	2.7	5
1365	Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review. <i>Rheumatology and Therapy</i> , 2022, 9, 975-991.	2.3	8
1367	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2022, 74, 1399-1408.	3.4	21
1368	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2022, 37, 1676-1683.	3.1	10
1369	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis and Rheumatology</i> , 2022, 74, 1464-1473.	5.6	12
1370	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0
1372	SMO3, an Anti-CD22 Antibody, Converts <i>Cis</i>-to-<i>Trans</i> Ligand Binding of CD22 against \pm 2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases. <i>Journal of Immunology</i> , 2022, 208, 2726-2737.	0.8	6
1373	Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. <i>Annual Review of Medicine</i> , 2023, 74, 339-352.	12.2	34
1374	Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human Bâ€lymphocyte Stimulating Factor Receptorâ€Antibody Fusion Protein, in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 1273-1283.	1.6	7
1375	Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 0, , .	3.3	0
1376	Recommendations for Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 617-636.	1.9	8
1377	The promise of precision medicine in rheumatology. <i>Nature Medicine</i> , 2022, 28, 1363-1371.	30.7	24
1378	Recent advances in immunotherapies for lupus nephritis. <i>Pediatric Nephrology</i> , 2023, 38, 1001-1012.	1.7	5
1379	Stem cell therapy in lupus. <i>Rheumatology and Immunology Research</i> , 2022, 3, 61-68.	0.8	5
1380	Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients. <i>Clinical Rheumatology</i> , 2022, 41, 3373-3382.	2.2	3
1381	Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. <i>Journal of Autoimmunity</i> , 2022, 132, 102861.	6.5	23
1382	Evaluating the Use of Glucocorticoids Among <scp>Belimumabâ€Treated</scp> Patients With Systemic Lupus Erythematosus in <scp>Realâ€World</scp> Settings Using the Rheumatology Informatics System for Effectiveness Registry. <i>ACR Open Rheumatology</i> , 2022, 4, 883-889.	2.1	7
1383	Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1409-1419.	0.9	9

#	ARTICLE	IF	CITATIONS
1384	Recent Advances in SLE Treatment Including Biologic Therapies. , 0, , .		0
1385	Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, <scp>Double-blind</scp>, <scp>Placebo-controlled</scp>, Multiple Ascending Dose Study. ACR Open Rheumatology, 2022, 4, 903-911.	2.1	4
1386	Safety and Efficacy of Switching Immunosuppressive Drugs for Maintenance Treatment in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study. Modern Rheumatology, 0, , .	1.8	0
1387	B-cell response in solid organ transplantation. Frontiers in Immunology, 0, 13, .	4.8	1
1388	B cell-targeted therapies in systemic lupus erythematosus. Journal of Autoimmunity, 2022, 132, 102873.	6.5	12
1389	Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell, 2022, 185, 3375-3389.e21.	28.9	33
1390	Management of non-renal manifestations of systemic lupus erythematosus: A systematic literature review for the <scp>APLAR</scp> consensus statements. International Journal of Rheumatic Diseases, 2022, 25, 1220-1229.	1.9	10
1391	Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy. Lupus, 2022, 31, 1456-1467.	1.6	2
1392	External Validation of the Lupus Multivariable Outcome Score for Systemic Lupus Erythematosus Trials. ACR Open Rheumatology, 0, , .	2.1	1
1393	Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience. Rheumatology, 0, , .	1.9	0
1394	Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus. Clinical Rheumatology, 2022, 41, 3735-3745.	2.2	2
1395	Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?. Frontiers in Immunology, 0, 13, .	4.8	7
1396	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. Frontiers in Immunology, 0, 13, .	4.8	5
1397	What is new in the treatment of Systemic Lupus Erythematosus?. Vnitřni Lekarství, 2022, 68, 273-278.	0.2	0
1398	Time for new therapeutic options in lupus nephritis. Joint Bone Spine, 2022, , 105451.	1.6	0
1399	Lupus nephritis: new progress in diagnosis and treatment. Journal of Autoimmunity, 2022, 132, 102871.	6.5	37
1400	Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-response. Journal of Clinical Pharmacology, 2023, 63, 105-118.	2.0	4
1401	Autoreactive B cells recruited to lungs by silica exposure contribute to local autoantibody production in autoimmune-prone BXSb and B cell receptor transgenic mice. Frontiers in Immunology, 0, 13, .	4.8	1

#	ARTICLE	IF	CITATIONS
1402	Will fecal microbiota transplantation eventually be an effective therapeutic strategy for systemic lupus erythematosus?. <i>Clinical Immunology</i> , 2022, 242, 109096.	3.2	3
1403	Systemic lupus erythematosus: history and modernity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 397-412.	1.0	11
1404	Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 5207.	2.4	1
1405	Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103188.	5.8	9
1406	Infections Associated with Systemic Lupus Erythematosus: Tackling Two Devils in the Deep Blue Sea. <i>Indian Journal of Rheumatology</i> , 2023, 18, S3-S11.	0.4	0
1407	Lupus Nephritis. , 2022, , 507-539.		0
1408	Therapeutic Human Monoclonal Antibodies. , 2022, , 401-418.		1
1409	A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab: Case report with review. <i>Modern Rheumatology Case Reports</i> , 2023, 7, 82-86.	0.7	3
1410	Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
1411	B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	13
1412	Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1413	Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. <i>Birth Defects Research</i> , 2023, 115, 188-204.	1.5	7
1414	Role of the Immune System in Renal Transplantation, Types of Response, Technical Approaches and Current Challenges. <i>Immuno</i> , 2022, 2, 548-570.	1.5	4
1415	Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With <scp>Long-term</scp> Clinical Outcomes: A <scp>Five-year</scp> Prospective Study. <i>Arthritis and Rheumatology</i> , 2023, 75, 401-410.	5.6	2
1416	Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	15
1417	Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2022, 387, 894-904.	27.0	37
1418	Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. , 0, , .		0
1419	MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus Natlonwide reGistry (LUNA) coHorT. <i>Lupus Science and Medicine</i> , 2022, 9, e000746.	2.7	0

#	ARTICLE	IF	CITATIONS
1420	Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 217-225.	0.9	9
1421	Investigational drugs for the treatment of kidney transplant rejection. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1087-1100.	4.1	5
1422	Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data. <i>Lupus</i> , 0, , 096120332211311.	1.6	1
1423	The Role of Anti-B Cell Activating Factor Therapy for Treating Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, CJN.11340922.	4.5	0
1424	Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis. <i>Global & Regional Health Technology Assessment</i> , 0, 9, 123-132.	0.1	0
1425	Novel and emerging treatment strategies for lupus nephritis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1283-1292.	3.1	5
1426	Autoantibodies - enemies, and/or potential allies?. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
1427	Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways. <i>Arthritis and Rheumatology</i> , 2023, 75, 553-566.	5.6	6
1428	Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. <i>Journal of Clinical Medicine</i> , 2022, 11, 6016.	2.4	8
1429	Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. <i>European Journal of Immunology</i> , 2023, 53, .	2.9	13
1430	Current views on lupus in children. <i>Current Opinion in Rheumatology</i> , 0, Publish Ahead of Print, .	4.3	4
1431	APRIL/BlyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model. <i>PLoS ONE</i> , 2022, 17, e0275564.	2.5	1
1432	Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus. <i>Lupus</i> , 0, , 096120332211372.	1.6	0
1433	Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses. <i>Modern Rheumatology</i> , 2023, 33, 751-757.	1.8	3
1435	Editorial: New biomarkers for the diagnosis and treatment of systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
1436	Long-term risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura and the role of anti-CD20 therapy. <i>Blood</i> , 0, , .	1.4	6
1437	Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades. <i>Internal Medicine</i> , 2022, 61, 3189-3196.	0.7	1
1438	Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSERVE Spain multicentre study. <i>Reumatología Clínica</i> , 2022, , .	0.5	1

#	ARTICLE	IF	CITATIONS
1439	Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. <i>Trials</i> , 2022, 23, .	1.6	8
1440	Multi-target therapy in a lupus patient with diffuse alveolar hemorrhage. <i>Lupus</i> , 0, , 096120332211369.	1.6	1
1441	Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 683-693.	8.0	18
1443	CARs: a new approach for the treatment of autoimmune diseases. <i>Science China Life Sciences</i> , 2023, 66, 711-728.	4.9	3
1444	Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. <i>JCI Insight</i> , 2022, 7, .	5.0	10
1445	Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and <scp>Meta-Analysis</scp>. <i>Arthritis Care and Research</i> , 2023, 75, 1838-1848.	3.4	5
1446	B cell depletion and inhibition in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 55-70.	3.0	3
1447	B-cell activating factor (BAFF) and its receptors'™ expression in pediatric nephrotic syndrome is associated with worse prognosis. <i>PLoS ONE</i> , 2022, 17, e0277800.	2.5	3
1448	Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	1.4	1
1449	Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	1.4	1
1450	Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study. <i>Lupus Science and Medicine</i> , 2022, 9, e000710.	2.7	0
1451	The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. <i>Lupus</i> , 2023, 32, 301-309.	1.6	6
1452	EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
1453	Unraveling the Link between Interferon-± and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15998.	4.1	4
1454	B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?. <i>Journal of Clinical Medicine</i> , 2023, 12, 18.	2.4	7
1455	A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's™ syndrome. <i>JCI Insight</i> , 2022, 7, .	5.0	23
1456	Editorial: Advances in systemic lupus erythematosus: The promises and pitfalls of personalized medicine and patient stratification. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
1457	Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort. <i>Rheumatology</i> , 0, , .	1.9	1

#	ARTICLE	IF	CITATIONS
1458	Improving measures of disease activity in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2023, 19, 193-202.	3.0	3
1460	Targeting type I interferons in systemic lupus erythematosus. Frontiers in Pharmacology, 0, 13, .	3.5	5
1461	Current perspectives on the diagnosis, assessment, and management of vasculitic neuropathy. Expert Review of Neurotherapeutics, 0, , 1-12.	2.8	0
1462	Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study. Rheumatology and Therapy, 0, , .	2.3	1
1463	Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence. Patient Related Outcome Measures, 0, Volume 14, 1-13.	1.2	2
1464	New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine, 2023, 90, 105523.	1.6	18
1465	ANCA-Associated Vasculitis, Anti-GBM Disease, and Lupus Nephritis. Nephrology Self-assessment Program: NephSAP, 2022, 21, 364-382.	3.0	0
1466	Actualit� du traitement du lupus en 2022. , 2022, , 19-26.		0
1468	Insights and strategies to promote immune tolerance in allogeneic hematopoietic stem cell transplantation recipients. , 2023, , 329-360.		0
1470	Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study. International Journal of Environmental Research and Public Health, 2023, 20, 1917.	2.6	0
1471	Autoimmune diseases. , 2023, , 123-244.		2
1472	Belimumab for the treatment of pediatric patients with lupus nephritis. Expert Opinion on Biological Therapy, 2023, 23, 243-251.	3.1	4
1473	Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Annals of Allergy, Asthma and Immunology, 2023, , .	1.0	1
1474	Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues. Frontiers in Immunology, 0, 14, .	4.8	0
1475	Performance of systemic lupus erythematosus responder index for detecting <sc>clinician-rated</sc> responders in patients with active systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2023, 26, 667-672.	1.9	2
1476	Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 6578.	4.1	8
1477	Pregnancy in Systemic Lupus Erythematosus Patients with Nephritis. , 0, , 100-104.		0
1478	Pathogenesis and treatment of Sjogren's syndrome: Review and update. Frontiers in Immunology, 0, 14, .	4.8	23

#	ARTICLE	IF	CITATIONS
1479	Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China. <i>Kidney Diseases (Basel, Switzerland)</i> , 2023, 9, 218-228.	2.5	1
1480	Inhibiting B cell activating factor attenuates preeclamptic symptoms in placental ischemic rats. <i>American Journal of Reproductive Immunology</i> , 2023, 89, .	1.2	3
1481	The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1482	Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus. <i>Lancet Rheumatology, The</i> , 2023, 5, e151-e165.	3.9	3
1483	Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives. <i>Lupus Science and Medicine</i> , 2023, 10, e000776.	2.7	5
1484	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). <i>Lancet, The</i> , 2023, 401, 1001-1010.	13.7	44
1485	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). <i>Lancet, The</i> , 2023, 401, 1011-1019.	13.7	53
1486	Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. <i>Annual Review of Immunology</i> , 2023, 41, 533-560.	21.8	28
1487	Treatment of lupus nephritis: consensus, evidence and perspectives. <i>Nature Reviews Rheumatology</i> , 2023, 19, 227-238.	8.0	17
1488	Immunopathogenesis of systemic lupus erythematosus. , 2023, , 265-292.		0
1489	The pathology and potential clinical applicability of interfering T cells in systemic lupus erythematosus. , 2023, , 349-372.		0
1490	Challenges in systemic lupus erythematosus: From bench to bedside. , 2023, , 293-331.		1
1491	Future landscape for the management of membranous nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 1228-1238.	2.9	3
1492	Combination strategies for lupus nephritis: facts and controversies. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 527-536.	3.0	2
1493	Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study. <i>Biomedicines</i> , 2023, 11, 962.	3.2	2
1494	Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State. <i>Rheumatology</i> , 0, , .	1.9	0
1495	Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	0
1496	Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data. <i>Lupus Science and Medicine</i> , 2023, 10, e000830.	2.7	1

#	ARTICLE	IF	CITATIONS
1497	A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol. <i>Trials</i> , 2023, 24, .	1.6	3
1498	Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2023, 62, i22-i29.	1.9	9
1499	Potential Therapeutic Value of the STING Inhibitors. <i>Molecules</i> , 2023, 28, 3127.	3.8	5
1500	Lupus Nephritis. , 2023, , 737-763.		0
1501	Challenges in the Development of drugs for Systemic Lupus Erythematosus: A Regulatory Perspective. , 0, , 1-13.		0
1504	Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Studyâ€”Joint and Skin (BeRLISS-JS). <i>Journal of Personalized Medicine</i> , 2023, 13, 691.	2.5	1
1505	Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. <i>Lupus Science and Medicine</i> , 2023, 10, e000907.	2.7	6
1506	Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy. <i>Cell Reports Medicine</i> , 2023, 4, 101036.	6.5	7
1507	Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study. <i>Lancet Rheumatology, The</i> , 2023, 5, e284-e292.	3.9	5
1508	Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream. <i>Journal of Clinical Medicine</i> , 2023, 12, 3348.	2.4	2
1509	Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. <i>Nefrologia</i> , 2023, , .	0.4	2
1510	Targeted Therapy for SLEâ€”What Works, What Doesnâ€™t, Whatâ€™s Next. <i>Journal of Clinical Medicine</i> , 2023, 12, 3198.	2.4	0
1511	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of <sc>BAFF</sc> and <sc>ICOSL</sc>: Analyses of Phase I Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 371-380.	4.7	3
1512	Current treatment of systemic lupus erythematosus: a clinician's perspective. <i>Rheumatology International</i> , 2023, 43, 1395-1407.	3.0	6
1513	Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis. <i>Renal Failure</i> , 2023, 45, .	2.1	3
1514	Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. <i>Rheumatology</i> , 2024, 63, 338-348.	1.9	8
1515	Telitacicept for autoimmune nephropathy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
1516	Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSERVE Spain multicentre study. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2023, 19, 312-318.	0.3	0

#	ARTICLE	IF	CITATIONS
1517	Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1157-1169.	2.5	0
1518	The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review. <i>Cureus</i> , 2023, , .	0.5	0
1519	Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 260-267.	1.0	0
1520	Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	3
1521	Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender. <i>Rheumatology & Autoimmunity</i> , 2023, 3, 115-119.	0.8	0
1522	Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab. <i>Rheumatology</i> , 2024, 63, 798-808.	1.9	1
1523	Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
1524	Application of Belizumab in Lupus Nephritis. <i>Advances in Clinical Medicine</i> , 2023, 13, 8421-8430.	0.0	0
1525	Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2023, 75, 1994-2002.	5.6	3
1527	Characterization of virus-mediated autoimmunity and the consequences for pathological process in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 0, , .	2.2	0
1528	Contemporary Monoclonal Antibody Utilization in Glomerular Diseases. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2023, 7, 276-290.	2.4	0
1529	Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus. <i>Life</i> , 2023, 13, 1496.	2.4	3
1530	Effect of Belimumab on Preventing de novo Renal Lupus Flares. <i>Kidney International Reports</i> , 2023, 8, 1822-1830.	0.8	1
1531	Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11179.	4.1	3
1532	Advances in natural products and antibody drugs for SLE: new therapeutic ideas. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1533	Targeted therapy in glomerular diseases. <i>Journal of the Formosan Medical Association</i> , 2024, 123, 149-158.	1.7	0
1534	Obixelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway <sc>Co-expression</sc> Patterns: A <sc>Double-blind</sc>, Randomized, <sc>Placebo-controlled</sc>, Phase 2 Trial. <i>Arthritis and Rheumatology</i> , 2023, 75, 2185-2194.	5.6	2
1535	Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	3.6	0

#	ARTICLE	IF	CITATIONS
1536	Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 2733-2742.	0.7	2
1537	Clinical research progress of novel biologics for the treatment of lupus nephritis. <i>Clinical and Experimental Medicine</i> , 0, , .	3.6	0
1538	Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. <i>Medicina (Lithuania)</i> , 2023, 59, 1362.	2.0	2
1539	Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study. <i>Immunity, Inflammation and Disease</i> , 2023, 11, .	2.7	0
1540	Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. <i>IScience</i> , 2023, 26, 107487.	4.1	0
1541	Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus. <i>Clinical Proteomics</i> , 2023, 20, .	2.1	1
1542	Targeting B cells for treatment of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 0, , .	4.3	0
1543	Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2023, 382, 578169.	2.3	0
1544	A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations. <i>Cureus</i> , 2023, , .	0.5	0
1545	Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
1546	Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis. <i>Journal of Clinical Rheumatology</i> , 0, , .	0.9	0
1547	What is the best instrument to measure disease activity in SLE? - SLE-DAS vs Easy BILAG. <i>Autoimmunity Reviews</i> , 2023, , 103428.	5.8	2
1548	Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report. <i>Medicine (United States)</i> , 2023, 102, e34800.	1.0	1
1549	hUC-MSc transplantation therapy effects on lupus-prone MRL/lpr mice at early disease stages. <i>Stem Cell Research and Therapy</i> , 2023, 14, .	5.5	1
1550	B cell metabolism in autoimmune diseases: signaling pathways and interventions. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1551	Daratumumab monotherapy for refractory lupus nephritis. <i>Nature Medicine</i> , 2023, 29, 2041-2047.	30.7	8
1552	B Cell Tolerance and Targeted Therapies in SLE. <i>Journal of Clinical Medicine</i> , 2023, 12, 6268.	2.4	0
1553	Targeting DORIS Remission and LLDAS in SLE: A Review. <i>Rheumatology and Therapy</i> , 2023, 10, 1459-1477.	2.3	1

#	ARTICLE	IF	CITATIONS
1554	A Practical Overview of the Articular Manifestations of Systemic Lupus Erythematosus. <i>Cureus</i> , 2023, , .	0.5	0
1555	Challenges in the diagnosis and management of SLE in India. <i>Clinical Immunology Communications</i> , 2023, 4, 65-69.	1.2	0
1556	Mitochondrial Lon protease promotes CD4+ T cell activation by activating the cGAS-STING-TBK1 axis in systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2023, 123, 110519.	3.8	0
1557	Management of Lupus Nephritis: New Treatments and Updated Guidelines. <i>Kidney360</i> , 2023, , .	2.1	0
1558	Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study. <i>Rheumatology</i> , 0, , .	1.9	1
1559	Musculoskeletal manifestations of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2023, , 101859.	3.3	1
1560	Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2023, , 101864.	3.3	1
1561	Targeted Treatment of Diseases of Immune Dysregulation. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 913-929.	1.9	0
1562	New and future therapies: Changes in the therapeutic armamentarium for SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2023, , 101865.	3.3	0
1563	Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1564	Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares. <i>Arthritis Care and Research</i> , 0, , .	3.4	2
1565	Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacisept Phase II Studies. <i>ACR Open Rheumatology</i> , 2023, 5, 536-546.	2.1	0
1566	Determination of plasma concentration of Belimumab by LC-MS/MS: Method development, validation, and clinical application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 236, 115730.	2.8	2
1567	Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 901-908.	4.1	0
1568	Concurrent Acute, Subacute, and Chronic Cutaneous Rashes in a Patient with Systemic Lupus Erythematosus. , 2023, 2, .		0
1570	Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). <i>BMC Rheumatology</i> , 2023, 7, .	1.6	1
1571	The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus Nephritis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15234.	4.1	0
1572	B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2023, 10, e000926.	2.7	0

#	ARTICLE	IF	CITATIONS
1593	SLE criteria are by necessity still based on clinical (and immunological) criteria items. Expert Review of Clinical Immunology, 2024, 20, 305-311.	3.0	0
1594	Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study. Clinical Rheumatology, 0, , .	2.2	0
1595	Real-World Effectiveness of Belimumab in Patients with Active Lupus. Journal of Clinical Medicine, 2023, 12, 7627.	2.4	0
1596	Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists. Annals of Pharmacotherapy, 0, , .	1.9	0
1597	Managing Lupus Nephritis in Children and Adolescents. Paediatric Drugs, 2024, 26, 145-161.	3.1	1
1598	Telitaccept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2024, 83, 475-487.	0.9	0
1599	Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Science and Medicine, 2023, 10, e001024.	2.7	0
1600	Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia. International Journal of Rheumatic Diseases, 2024, 27, .	1.9	0
1601	Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment. Best Practice and Research in Clinical Rheumatology, 2023, , 101925.	3.3	0
1602	An overlapping case of IgG4-related disease and systemic lupus erythematosus treated with belimumab: a case-based review. Rheumatology International, 2024, 44, 549-556.	3.0	0
1603	Hurdles in new drug development in rheumatic diseases. Joint Bone Spine, 2024, 91, 105672.	1.6	0
1604	Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids. Korean Journal of Internal Medicine, 2024, 39, 338-346.	1.7	0
1605	Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus. Frontiers in Immunology, 0, 14, .	4.8	0
1606	Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Science and Medicine, 2024, 11, e001068.	2.7	0
1607	Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab. Rheumatology, 0, , .	1.9	0
1608	Actualit�s th�rapeutiques dans la n�phropathie lupique. , 2023, , 51-58.		0
1609	Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better <sc>Health�Related</sc> Quality of Life. Arthritis Care and Research, 0, , .	3.4	0
1610	Nivolumab treatment in a mucosal melanoma patient with pre-existing systemic lupus erythematosus: A case report with literature review. Acta Facultatis Medicae Naissensis, 2023, 40, 505-511.	0.4	0

#	ARTICLE	IF	CITATIONS
1611	Progress in Clinical Research on Belimumab in the Treatment of Rheumatic Diseases. <i>Advances in Clinical Medicine</i> , 2024, 14, 1673-1683.	0.0	0
1612	Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies. <i>Antibodies</i> , 2024, 13, 10.	2.5	0
1613	Therapeutic Targeting of B Cells and Plasma Cells with a Focus on Multiple Sclerosis and Other Autoimmune Conditions. , 2024, , 425-435.		0
1614	Homeostatic Versus Pathogenic Autoantibodies: Origin, Structure and Effector Functions. , 2024, , 387-412.		0
1615	CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy. <i>Joint Bone Spine</i> , 2024, 91, 105702.	1.6	0
1616	Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2024, 43, 1023-1035.	2.2	1
1617	New guidelines and therapeutic updates for the management of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2024, 33, 344-353.	2.0	0
1618	From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1620	Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review. <i>Current Therapeutic Research</i> , 2024, 100, 100738.	1.2	0
1621	Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons. <i>Expert Review of Clinical Immunology</i> , 0, , 1-16.	3.0	0
1622	Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice. <i>Lupus</i> , 2024, 33, 481-489.	1.6	0
1623	Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 0, , .	1.9	0
1624	An update on clinical trials for cutaneous lupus erythematosus. <i>Journal of Dermatology</i> , 0, , .	1.2	0
1627	Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review. <i>Immunologic Research</i> , 0, , .	2.9	0
1628	Improving Drug Trial Success Rates in Systemic Lupus Erythematosus: Endotyping-based Patient Stratification Could be the way Forward. <i>Indian Journal of Rheumatology</i> , 2024, 19, 62-69.	0.4	0
1629	Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates. <i>Journal of Medical Economics</i> , 2024, 27, 23-34.	2.1	0